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ECCO statement 5A
Mesalazine 1 g suppository daily is the preferred
initial treatment for mild or moderately active
proctitis [EL1b, RG B]. Mesalazine foam enemas
are an effective alternative [EL1b]. Suppositories
may deliver drug more effectively to the rectum
and are better tolerated than enemas [EL3, RG C].
Combining topical mesalazine with oral mesala-
zine or topical steroid, may bemore effective than
either alone and should be considered for escala-
tion of treatment [EL1b, RG B]. Oral mesalazine
alone is less effective [EL1b]
26 S.P.L. Travis et al.5. Medical management of active
ulcerative colitis
5.1. General
The general principles for treating active ulcerative colitis
are to consider the activity, distribution (proctitis, left-sided,
extensive,1 and pattern of disease (relapse frequency, course
of disease, response to previous medications, side-effect
profile of medication, extra-intestinal manifestation),
before treatment decisions are made in conjunction with
the patient.
5.1.1. Disease activity
The principal scoring systems used for clinical trials are
covered in Section 5.1.2 and have been comprehensively
reviewed.2 Some additional points are clinically relevant.
In clinical practice it matters most to distinguish severe
ulcerative colitis necessitating hospital admission from
those with mild or moderate disease who can generally
be treated as outpatients. The simplest, best validated
and most widely used index for identifying acute severe
UC remains that of Truelove & Wi_tts 3: any patient who
has a bloody stool frequency ≥6/day and a tachycardia
(N90 bpm), or temperature N37.8 °C, or anaemia
(haemoglobin b10.5 g/dL), or an elevated ESR (N30 mm/
h) has severe ulcerative colitis (Table 1.3). This index has
been used in 20/32 studies of intensive intravenous
treatment for severe UC.4 Only one additional criterion
in addition to the bloody stool frequency ≥6/day is
needed to define a severe attack.5 While these criteria
have the major limitation of being unresponsive and
cannot track the course of disease, they do distinguish
the severe from the moderate or mild and have value in
everyday practice because they are easy to use, which no
other index achieves. It should be standard practice to
confirm active colitis by sigmoidoscopy or proctoscopy
before starting treatment. Rectal mucosal biopsy helps
exclude unexpected causes of symptoms similar to active
disease (such as cytomegalovirus, amoebic, or other
infection, rectal mucosal prolapse, Crohn's disease, or
even irritable bowel syndrome and haemorrhoidal
bleeding).
5.1.2. Approach
Patients should be encouraged to participate actively in
therapeutic decisions. In a systematic review of clinical
trials, a mean 15% (95%CI 10–21%) of patients entered
remission when receiving placebo.9 Prescribing no treat-
ment, however, is rarely an option, because rectal
bleeding and urgency are sufficiently concerning to the
patient to justify topical therapy even if no systemic
therapy is recommended.
The appropriate choice of medication depends on many
factors that are best tailored to the individual. Despite
general agreement that treatment decisions for active UC
should be based on the distribution, activity and pattern
of disease, numbers in clinical trials often become too
small for statistically valid conclusions to be drawn when
patients are stratified according to the distribution and
pattern of disease.7 Different galenic preparations are
released at different sites and may have local activity(such as mesalazine preparations, budesonide, or types of
enema). The choice is influenced by the balance between
drug potency and side-effects; previous response to
treatment (especially when considering treatment of a
relapse, treatment of steroid-dependent or -refractory
disease, or immunomodulator-refractory disease, Section
5.3); and the presence of extraintestinal manifestations
(indicating the need for systemic therapy).
5.2. Treatment according to site of disease and
disease activity
5.2.1. ProctitisActive colitis limited to the rectum should first be
treated topically. Suppositories are more appropriate than
enemas, because suppositories target the site of inflam-
mation; only 40% of foam enemas and 10% of liquid enemas
can be detected in the rectum after 4 hr.10 Topical
mesalazine (5-ASA) induced remission in active proctitis
and distal colitis in 31–80% (median 67%) compared to 7–
11% given placebo in a meta-analysis of 11 trials in 778
patients.11 Topical mesalazine is at least twice as effective
as topical steroids whether for symptoms (OR 2.42, 95%CI
1.72–3.41), endoscopy (OR 1.89, 95%CI 1.29–2.76), or
histology (OR 2.03, 95%CI 1.28–3.20).12 Mesalazine suppo-
sitories 1 g daily are highly effective.13 There is no dose
response to topical therapy above a dose of 1 g mesalazine
daily. Clinical (and endoscopic) remission can occur in up to
64% (52%) within 2 weeks.13 Topical steroids should be reserved
as second line therapy for patientswho are intolerant of topical
mesalazine.14 Topical mesalazine is more effective than oral
mesalazine for proctitis,15 but the combination of oral and
topical mesalazine may be better than either alone for colitis
b50 cm from the anal verge.16 There have been no trials on
combination therapy for proctitis alone. Combining topical
mesalazine and steroids also helps: beclomethasone dipropio-
nate (3mg) andmesalazine (2 g) enemas produced significantly
better clinical, endoscopic and histological improvement than
either agent alone.17 Patients who fail to improve on topical
mesalazine and topical corticosteroids should be treated with
additional oral mesalazine or, alternatively, oral prednisolone,
as if the colitis was more extensive or severe (below).
Treatment of refractory proctitis is discussed in Section 5.2.7.
27ECCO Consensus on UC: Current management5.2.2. Left sided colitisECCO statement 5B
Left-sided active ulcerative colitis of mild-moderate
severity should initially be treated with topical
aminosalicylates [EL1b, RG B] combined with oral
mesalazineN2 g/day [EL1a, RGA]. Topical steroids or
mesalazine alone are also effective, but less effec-
tive than combination therapy [EL1b, RG B]. Topical
mesalazine is more effective than topical steroid
[EL1a, RG A]. Oral aminosalicylates alone are less
effective [EL1a, RG A]. Systemic corticosteroids are
appropriate if symptoms of active colitis do not
respond rapidly to mesalazine [EL1b, RG C]. Severe
left-sided colitis is usually an indication for hospital
admission for intensive treatment with systemic
therapy [EL1b, RG B]
ECCO statement 5C
Extensiveulcerative colitis ofmild-moderate severity
should initially be treated with mesalazine N2 g/day
[EL1a, RG A], combined with topical mesalazine
[EL1b, RG A]. Oral aminosalicylates alone induce
remission only in a minority of patients [EL1a, RG A].
Systemic corticosteroids are appropriate if symp-
toms of active colitis do not respond rapidly to
mesalazine [EL1b, RG C], or who are already taking
appropriate maintenance therapy. Severe extensive
colitis is usually an indication for hospital admission
for intensive treatment [EL1b, RG B]Combined oral and topical mesalazine therapy is re-
commended.14 There has been just one trial on 60 patients of
combined therapy for distal colitis compared to oral or topical
therapy alone, showing it toworkmore rapidly andeffectively.16
However, extrapolation from a trial of combination therapy for
extensive colitis,18 evidence that topical therapy achieves
higher rectal mucosal 5ASA concentrations than oral therapy19
and is associated with improved clinical outcome,19,20 are
consistent with the recommendation.
Most therapeutic trials of mild or moderate active colitis
include patients with any disease distribution other than
proctitis, but both oral and topical aminosalicylates (mesala-
zine) are effective for left-sided colitis. In a meta-analysis of
oral 5-ASA compounds for active colitis,21 mesalazine was more
than twice as effective as placebo (OR 0.40, 95%CI 0.30–0.53),
but not significantly better than sulphasalazine (OR 0.83, 95%CI
0.60–1.13) for the failure to induce global clinical improvement
or remission. Therewas a trend formesalazine to be better than
sulfasalazine for endoscopic improvement (OR 0.66, 95%CI
0.42–1.04) and mesalazine is better tolerated than sulfasala-
zine.21 This is a modest benefit— (NNT to induce remission=10
(95% CI 7–21), and NNT=4 to induce response or remission (95%
CI 3–6)22). A systematic review of 9 placebo controlled trials of
oral aminosalicylates for active ulcerative colitis showed the
overall remission rate to be only 20%.22 Two further placebo
controlled trials of a multimatrix mesalazine formulation for
mild-moderate UC have been published more recently,23,24 as
well as a combined analysis.25 The first study randomized 280
patients to either MMx 4.8 g once daily, MMx 1.2 g twice daily, or
placebo for 8 weeks. The primary endpoint was remission at
8 weeks. Once and twice daily dosing produced similar results,
with remission rates of 29% and 34% respectively, compared to
13% on placebo (pb0.01)23 (see also Section 6.2.1). A further
placebo-controlled study compared MMx mesalazine with
Asacol® in 346 patients with active, mild-to-moderate UC.24
Clinical and endoscopic remission was achieved in 40.5% given
MMxmesalazine 2.4 g/day once daily and 41.2% given 4.8 g/day
once daily compared to 22.1% on placebo (p=0.01 and 0.007
respectively) and 32.6% given Asacol® (ns).
Meta-analysis of mesalazine for active UC shows a dose-
response for improvement from b2.0 g, 2.0–2.9 g and N3.0 gdaily (p=0.002), but not for remission.21 This trend is confirmed
by a trial of 4.8 gmesalazine (Asacol®) vs 2.4 gmesalazine daily
in 268 patients with moderately active UC, half of whom had
distal disease. Treatment response was 71.8% in the 4.8 g group
and 59.2% in the 2.4 g group (p=0.036), although remission rates
wereonly 20.2% and17.7% respectively (ns).8 Treatmentworked
just as well for left-sided disease as for extensive colitis, and
there was no increase in side-effects at the higher dose, so
higher doses of mesalazine are recommended for moderately
active colitis. A peripheral benefit is a reduction in the median
time to cessation of rectal bleeding (from 16 days to 9 days
(pb0.05)) at the higher dose. This gives a useful timescale for
determining the speed of response. If rectal bleeding persists
beyond 10–14days, then the response canbe said to be slowand
therapy augmented, which usually means decisive treatment
with steroids.
There is something of a transatlantic divide on the threshold
for using steroids. The practice inmany European countries is to
introduce oral steroids at an early stage, because aminosalicy-
lates cannot match the speed of response for patients suffering
miserable symptoms. The US concern about steroid-induced
side-effects is shared by their patients, but may also be self-
fulfilling. Late introduction of steroids selects a more refractory
population. Steroids with a colonic release mechanism and low
systemicbioavailabilty suchasbeclomethasonediproprionateor
budesonide are becoming available. In the largest and most
recent study of 177 patients with active left-sided or extensive
colitis, beclomethasone diproprionate 5 mg/day had an effect
similar to that of 2.4 gmesalazine, but without systemic steroid
side-effects.26
5.2.3. Extensive ulcerative colitisThe approach is similar to that described for left-sided
colitis, with the important caveat that there should be
a lower threshold for decisive treatment with systemic
steroids. Oral mesalazine is effective,27 but combination
with topical mesalazine is better. Oral mesalazine
(Pentasa®) 4 g/day with a 1 g mesalazine enema in 116
patients induced clinical remission by 8 weeks in 64%
compared to 43% on oral mesalazine alone (p=0.03).18
This confirms that added benefit of topical mesalazine for
extensive colitis. Failure of mild or moderately active
disease to respond within 2 weeks to mesalazine is an
indication to consider oral prednisolone. Similarly, if a
ECCO statement 5E
Severe active ulcerative colitis with signs of systemic
toxicity should be treated in hospital [EL5, RGD]with
intravenous steroids (such as methylprednisolone
60 mg or hydrocortisone 400 mg daily) [EL1b, RG B].
Monotherapy with intravenous ciclosporin (to
achieve a minimum therapeutic concentration)
[EL1b, RG C] is an option for patients intolerant of
intravenous steroids. Patients are best cared for
jointly by a gastroenterologist and colorectal sur-
geon [EL5, RG D]
28 S.P.L. Travis et al.patient already on mesalazine N2 g/day or immunomodulators
as maintenance therapy has a relapse, decisive treatment
with steroids is considered appropriate. The reason for this
proactive approach is the risk of complications (including
toxic dilatation) in patients with extensive disease who are
under-treated.
Treatment with oral and rectal corticosteroids is based
on two early studies on active UC of any extent, including
extensive colitis. Oral prednisolone (starting at 40 mg
daily, with steroid enemas) induced remission in 77% of 118
patients with mild to moderate disease within 2 weeks,
compared to 48% treated with 8 g/day sulphasalazine and
steroid enemas.28 Similar findings were reported by
Lennard-Jones,29 who found the combination of oral and
rectal steroids to be better than either alone. An ap-
propriate regimen for moderately active disease is pre-
dnisolone 40 mg/day for 1 week, 30 mg/day for 1 week,
then 20 mg/day for 1 month before decreasing by 5 mg/
day/week. Many different regimes are used, but it is
sensible to have a standard approach at any single cen-
tre, so that steroid-dependence is recognised at an ear-
ly stage and a decision to start immunomodulators is
facilitated. Shorter courses (b3 weeks) are associated with
early relapse and doses of prednisolone b15 mg day are
ineffective for active disease.30 Oral steroids with low
systemic bioavailability (budesonide or prednisolone meta-
sulphobenzoate, with colonic release mechanisms) are
available or being developed.31,32
5.2.4. Severe ulcerative colitis of any extent
Acute severe ulcerative colitis is a potentially life-threaten-
ing condition. The only prevalence data date from 1963: 47/
250 (18.8%) first attacks and 109/619 (17.6%) of all patients
have a severe attack as defined by the criteria in Statement
5D.33 To grasp the implications of current medical and
surgical therapy requires knowledge of the historical
context.
In 1933, 16/21 (75%) died in the first year after
acute presentation with ulcerative colitis in Birmingham34
and in 1950 a mortality of 22% was reported from Oxford
among 129 cases in the first year after diagnosis.6 In 1955
the introduction of steroid therapy reduced mortality of
severe colitis to 7%, compared to 24% in the placebo group3
and it is now b1% in specialist centres.35 Nevertheless, the
response to steroids of severe colitis has remained un-
changed for 50 years.3,4 In view of this and the 29%
colectomy rate (95%CI 28–31%4), the Consensus believes
that patients meeting these criteria are best admitted to
hospital for intensive treatment. Management involves
more than pharmacotherapy.ECCO statement 5D
Severe active ulcerative colitis is best defined by
Truelove and Witts' criteria [EL3, RG C]. Patients
with bloody diarrhoea ≥6/day and signs of
systemic toxicity (tachycardia N90 bpm, fever
N37.8 °C, Hb b10.5 g/dL, or an ESR N30 mm/h)
should be admitted to hospital for intensive
treatment [EL5, RG D]5.2.4.1. Investigations on admission. See Section 7.5.3.
5.2.4.2. Therapeutic approach. Intravenous corticoster-
oids remain the mainstay of conventional therapy for acute
severe colitis,36 although details (such as the value of
antibiotics or parenteral nutrition) are debated by some. As
therapeutic options increase (ciclosporin, tacrolimus, or
infliximab among others), so too does the opportunity for
procrastinating about surgical decisions. The principal clinical
dilemmas are how to identify at an early stage those who are
likely to need colectomy, and when to start rescue medical
therapy in time so that surgery, if it becomes necessary, is not
inappropriately delayed. The two are not mutually exclusive
and management demands the most taxing clinical judge-
ment. Only one patient in a hundred need die as a result of
complications caused by operating too late to negate any
benefits ofmedical therapy. This iswhy it is recommended that
patients should be treated in hospital jointly by a specialist
Gastroenterologist and Colorectal surgeon.
5.2.4.3. Conventional therapy.Treatment with corticosteroids should not be delayed
awaiting microbiological results for possible infective causes.
Corticosteroids are generally given intravenously using, for
example, methylprednisolone 40 mg or hydrocortisone 100 mg
four times daily. Higher doses (including 500 mg–1 g methyl-
prednisolone) are no more effective, but lower doses are less
effective.4,37 Bolus injection is as effective as continuous
infusion.38 Treatment is usually given for about 5 days, since
extending therapy beyond 7 to 10 days carries no benefit.4
In a systematic review of 32 trials of steroid therapy for
acute severe colitis involving 1991 patients from 1974–2006,
the overall response to steroids (intravenous hydrocortisone,
methylprednisolone, or betamethasone) was 67% (95%CI 65–
69%, or 1429/1991).4 Out of the 1991 patients, 565 (29%, 95%
CI 28–31%) came to colectomy. Mortality was 1% (22/1991,
95% CI 0.7–1.6%) and none of these outcomes changed
between 1974 and 2006 (R2 =0.07, p=0.8). Because of
substantial heterogeneity, it was not possible to discriminate
between complete and partial responses to steroids. Only a
minority (100/1991) received ciclosporin (below).
Other measures are considered appropriate in addition to
intravenous steroids:
• Intravenous fluid and electrolyte replacement to correct
and prevent dehydration or electrolyte imbalance.
ECCO statement 5F
The response to intravenous steroids is best
assessed objectively (by stool frequency, CRP
and abdominal radiography) on or about the third
day [EL2b, RGB]. Surgical options should be
considered and discussed at this stage or earlier.
Second line therapy with either ciclosporin [EL1b,
RG B], or infliximab [EL1b, RG B] or tacrolimus
[EL1b, RG B] will often be appropriate. If there is
clinical deterioration colectomy is recommended.
If there is no improvement within a further 4–
7 days, colectomy should usually be recommended
[EL5, RG D]. Third line therapy may be considered
at a specialist centre
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almost invariably necessary. Hypokalaemia or hypomag-
nesaemia can promote toxic dilatation.39
• Sigmoidoscopy or proctosopy and biopsy to confirm the
diagnosis and exclude cytomegalovirus infection.
• Stool cultures and assay for Cl difficile toxin.
• Subcutaneous heparin to reduce the risk of
thromboembolism.40
• Nutritional support if the patient is malnourished. Enteral
nutrition is most appropriate and associated with sig-
nificantly fewer complications than parenteral nutrition
in acute colitis (9% vs 35%41,). Bowel rest through in-
travenous nutrition does not alter the outcome,42 but
some centres use a food challenge after 5 days in an
attempt to discriminate between complete and partial
responders to intensive therapy.
• Withdrawal of anticholinergic, antidiarrhoeal agents,
NSAID and opioid drugs, which risk precipitating colonic
dilatation.39
• Topical therapy (corticosteroids or mesalazine) if toler-
ated and retained, although there have been no systema-
tic studies in acute severe colitis.36
• Antibiotics only if infection is considered (such as in an acute,
first attack of short duration, or after recent admission to
hospital), or immediately prior to surgery. Controlled trials of
oral or intravenous metronidazole, tobramycin, ciproflox-
acin or vancomycin in acute colitis have shown no consistent
benefit in addition to conventional therapy.43–48
• Blood transfusion to maintain a haemoglobin N10 g/dl.
Ciclosporinmonotherapy (CsA,4mg/kg/day intravenously) is
as effective as intravenous methylprednisolone (MeP) 40 mg/
day for acute severe colitis. In a randomized trial there was a
response in 10/15 CsA patients vs 8/15 MeP patients.49
Furthermore, half of all patients in another study comparing
low dose with high dose CsA50 also received CsA monotherapy,
without concomitant intravenous steroids. Consequently mono-
therapy with CsA is a useful option in those patients with severe
colitis when steroids are best avoided, such as those susceptible
to steroid-psychosis (schizophrenics or previous psychosis), or
for some other reason (concomitant osteoporosis, diabetes, or
personal preference).
5.2.5. Intravenous-steroid resistant ulcerative colitis of
any extent
The timing of colectomy for severe colitis remains one of the
most difficult decisions that a gastroenterologist has to make.
No individual patient wants a colectomy, but it is becoming
easier for physicians to aquiesce with every patient who does
not want a colectomy as therapeutic options increase. The
question is how to do this safely. There are two principal
options that can be added to intravenous steroids: calcineurin
inhibitors (ciclosporin or tacrolimus) or infliximab (IFX).
Simple, objective measures are needed to aid decision-
making. Factors that predict the need for colectomy in acute
severe colitis can broadly be divided into clinical, biochem-
ical and radiological markers. Genetic polymorphisms have
the potential to predict the outcome of disease in an
individual from the time of diagnosis51,52 but they cannot be
used for decision-making when colectomy is imminent.
Clinical markers depend on the objective measures of
stool frequency, or temperature. A stool frequency N12/dayon day 2 was associated with 55% colectomy,53 while a
frequency N8/day on day 3 of intensive treatment predicted
colectomy in 85% on that admission (‘Oxford index’).5 This
latter measure has been validated: a frequency N4 and CRP
N25 mg/L on day 3 (or when the stool frequency×0.14CRP is
N8 on day 3: ‘Sweden index’) predicted colectomy in 75%.54
More recently, CRP and stool frequency on day 3, as well as
temperature in children with acute severe colitis predicted
the need for colectomy, in studies that developed a Pediatric
UC Activity Index55,56 (Section 11.3.3).
Biochemical markers include CRP, albumin and pH. An ESR
N75 or a pyrexia N38 °C on admission have been associated
with a 5–9-fold increase in the need for colectomy in a
prospective study of 67 patients.57 In this study, lack of
response to steroids was predicted by b40% reduction in
stool frequency within 5 days. Nevertheless, patients (and
their doctors) prefer to know an absolute estimate of the
likelihood of colectomy, rather than relative measures. A
retrospective study of 167 patients in whom a high pro-
portion (40%) came to colectomy, developed a numerical
score combining mean stool frequency over 3 days, presence
or absence of colonic dilatation and hypoalbuminaemia
(b30 g/L) on admission that was associated with the need for
colectomy in up to 85%.58 This needs prospective validation.
Radiological criteria include the presence of colonic di-
latation N5.5 cm (associated with a 75% need for colectomy),
or mucosal islands on a plain abdominal radiograph (75%
colectomy).53 The presence of an ileus (indicated by 3
or more small bowel loops of gas) was associated with
colectomy in 73% in a retrospective study,59 but only 50% in a
prospective study from the same institution.5 The depth of
colonic ulceration after gentle air insufflation identified 42/
49 patients with deep ulcers that were associated with the
need for colectomy,60 but this is not widely used in clinical
practice.
Indices exist to be applied, as a threshold for triggering
appropriate action at an early stage. This means surgical
consultation and assessment by a stomatherapist in addition
to augmenting medical treatment. The CRP and stool fre-
quency criteria5 are the simplest objective measure, but
neither immutable nor always reproduced. Other criteria
may do as well, but must be as straightforward so that a
decision to start a calcineurin inhibitor, infliximab, or pro-
ceed to colectomy is not inappropriately delayed.
30 S.P.L. Travis et al.5.2.5.1. Ciclosporin (CsA). A placebo-controlled trial in
1994 identified CsA as potential rescue therapy for intrave-
nous steroid-resistant UC (IVSR-UC).61 Nine of 11 patients
failing steroids improved on ciclosporin whilst all 9 on
placebo failed to improve (RR 0.18, 95%CI 0.05–0.64). How-
ever, 3/11 and 4/9 eventually underwent colectomy in the
treatment and placebo groups respectively. The narrow
therapeutic index of CsA and its side-effect profile has
limited acceptability. In 2001, out of the 116 consecutive
patients admitted to 29 UK hospitals with severe UC, only 17
(15%) received CsA and only 7 of 33 (21%) who came to
colectomy had received CsA.62 In nine studies that used CsA
as rescue therapy in the systematic review of severe colitis,
only 100/622 (16%) patients treated received CsA.4 The short
term response was 51% (95% CI 41–60%) and 29% colectomy
(95% CI 25–32), but other case series report 70–80% early
response.63–65 Concerns about early toxicity have been
partly addressed by low dose (2 mg/kg) intravenous induc-
tion therapy (Section 5.4.7). In the largest randomized study
of CsA to date, 73 patients were randomized to either 2 mg/
kg or 4 mg/kg of intravenous CsA.50 Response rates at 8 days
were similar in both groups (83% and 82% respectively), with
9% coming to colectomy in the 2 mg/kg group and 13% in the
4 mg/kg group. The long-term outcome indicates that a
minority avoid colectomy. In two series, 58% of 76 patients64
and 88% of 142 patients65 came to colectomy over 7 years. A
Cochrane review66 concluded that numbers in controlled
trials were so few (only 5049,61) that there was limited
evidence for CsA being more effective than standard treat-
ment alone for severe UC.
5.2.5.2. Tacrolimus. Tacrolimus is another calcineurin
inhibitor, acting through a mechanism similar to CsA (Section
5.4.7). One randomised controlled trial has been performed
in ulcerative colitis that included 27/60 patients with acute
severe colitis.67 9/16 had a partial response to 0.05 mg/kg/
day adjusted to trough levels (up to 15 ng/mL), compared to
2/11 on placebo and the remainder had no response. Results
did not reach significance. Case series have shown broadly
similar results to ciclosporin after both intravenous (0.01 to
0.02 mg/kg) and oral (0.1 to 0.2 mg/kg) administration
(Table 5.2). It carries many of the risks (including nephro-
toxicity) of ciclosporin, although tacrolimus is a more ef-
fective immunomodulator than ciclosporin in renal or liver
transplantation (see Table 5.1).68,69
5.2.5.3. Infliximab. Infliximab as a single dose (5 mg/kg)
may also be effective rescue therapy. A Swedish–Danish
study treated 45 patients (24 IFX and 21 placebo with
continued intravenous betamethasone).73 7/24 in the IFXTable 5.1 Case series of tacrolimus for steroid-refractory ulcera
similar patients
Series n Response
Ciclosporin (iv 4 mg/kg, then oral) 76 56/76
Tacrolimus iv 0.01/oral 0.2 mg/kg 38 18/38
Tacrolimus iv 0.01 mg/kg 23 22/23
Tacrolimus oral 0.15 mg/kg 9 9/9group and 14/21 in the placebo group had a colectomy
within 3 months (p=0.017; OR 4.9, 95% CI 1.4–17). No
patient died. Two different scores were used to identify
patients before randomization to IFX or placebo. The
Sweden Index54 on day 3 identified sicker patients at an
earlier stage than the Seo Index74 calculated on day 5–7. It
was the group with less active disease after 5–7 days of
intravenous steroids who benefited most from IFX. There
have been other small studies of IFX for acute severe colitis
refractory to steroids that have not shown a difference in
colectomy.75–77 It should be noted that hospitalized
patients with severe colitis represent a very different
population to the outpatients in the ACT 1 & 2 studies78 (see
Section 5.4.3). A large controlled trial is needed, because
case series report 20%, 33%, 57% or 75% ultimately coming to
colectomy after IFX for intravenous-steroid resistant
ulcerative colitis.79–82
5.2.5.4. Selection. A recommendation on the best choice
between calcineurin inhibitors and IFX in addition to
intravenous steroids is not possible until there has been a
comparative, randomised controlled trial. Controlled trials
comparing CsA and IFX are n progress (2007/08). The in-
dividual circumstances of each patient have always to be
considered. If a patient has acute severe colitis despite ex-
isting treatment with an immunomodulator at an appro-
priate dose and duration, then there is little that medical
therapy can hope to offer since it is unlikely that remission
can be maintained. The effect of IFX as maintenance therapy
in these circumstances is unclear: such patients are a
different to those in the ACT trials and the risks, as well
as the potential benefit, of deferring (or even avoiding)
colectomy need careful discussion with individual patients.
Many gastroenterologists will be more familiar with the
adverse-event profile of IFX compared to CsA or tacrolimus.
The short half life of CsA, however, is a potential advantage
compared to IFX. Consequently if CsA does not work, it is only
a matter of hours before it disappears from the circulation,
while IFX will circulate for weeks. This may matter if
colectomy is performed, since septic complications are the
major cause of post-operative morbidity and mortality.82
Although IFX is reported not to increase post-operative
sepsis,83 no data are available that relate only to
emergency colectomy for sick patients with acute severe
UC (Section 7.6.3). In general only a single attempt at
rescue therapy with a calcineurin inhibitor or IFX should be
considered before colectomy, after careful discussion
between the patient, gastroenterologist and colorectal
surgeon about the options and potential outcomes. If
doubt persists, specialist advice should be sought at antive colitis, compared to a case series of ciclosporin therapy in
Colectomy at Ref
1–3mo 1 year 2 year
10/76 16/76 16/76 64
3/38 12/38 19/38 70
2/23 3/23 71
1/9 – 3/9 72
31ECCO Consensus on UC: Current managementearly stage from a referral centre. Use of IFX with CsA has
been associated with a particularly high rate of adverse
events (see Section 7.6.3).
5.2.6. Toxic dilatation and complications of severe
ulcerative colitis
5.2.6.1. Toxic megacolon. Toxic dilatation (megacolon)
represents the end of a spectrum of severe colitis that has
been unrecognized, undertreated, or refractory to appropriate
treatment. It is defined as total or segmental non-obstructive
dilatation of the colon N6.0 cm associated with systemic
toxicity.39,84 The incidence has never been studied system-
atically. About 5% of patients with acute, severe colitis
admitted to hospital will have toxic dilatation.39 Metabolic
disturbance (hypokalaemia or hypomagnesaemia), bowel pre-
paration, or anti-diarrhoeal therapy have been associated with
toxic dilatation,39 so these should be corrected or avoided.
Earlier diagnosis of severe colitis, more intensive medical
management and earlier surgery has reduced the incidence of
toxic megacolon complicating ulcerative colitis, but the
incidence for infective colitis is rising, reflecting the increasing
prevalence and severity of pseudomembranous colitis.85
The key aspects of management are aggressive medical
therapy and early surgical decision making. It is no different
to conventional therapy for acute severe colitis, except that
metronidazole 500 mg three times daily is appropriate on
empirical grounds in case of an infective aetiology. The
combination of steroids and antibiotics is safe even for
infective colitis; steroids reduce inflammation in pseudo-
membranous colitis.86 Nasogastric suction cannot be ex-
pected to decompress the colon and is unnecessary. The
classic knee-elbow position may relieve distension,87 but is
generally impracticable. A senior surgical opinion is best
sought on the day of admission. It should be made clear to all
that there is a 24 h window of opportunity for medical
treatment to work and that if there is no improvement then
early colectomy will be necessary.
5.2.6.2. Perforation, haemorrhage and others. Perforation
is themost serious complication of acute severe colitis, almost
invariably associated with colonoscopy or toxic dilatation
where colectomy has been inappropriately delayed. It carries
a mortality of up to 50%.39 Other complications appear
exceptional, including massive haemorrhage (1/66 patients
operated on for acute severe colitis in one series88), cerebral
sinus thrombosis40 and a poorly recognised panenteritis.89–91
In a review of 158 middle-aged or older American patients
with ulcerative colitis, however, 20/158 had toxic dilatation,
perforation or massive haemorrhage and 7/20 died.92
5.2.6.3. Long term outcome of severe colitis. The long
term outcome after admission with acute severe ulcerative
colitis is not good. When the outcome of a small, but
prospectively-collected cohort of patients who had avoided
surgery on the index admission was reexamined after
15 years, 8/22 (36%) complete responders to steroids came
to colectomy, compared to 8/10 incomplete responders
(stool frequency N3/day, or those with visible blood in the
stools at day 7, p=0.082).93 Median time to colectomy was
33.0 months (CI 12.6–67.1) for complete responders vs
6.0 months (95% CI 0.9–17.7) for incomplete responders(p=0.033). The longest period of steroid-free remission was
a median 45.0 months (CI 28.2–63.2, range 0–120) for
complete, but a median 8.5 months (CI 4.3–22.1, range 1–
35) for incomplete responders (p=0.017). Data on the
burden of medical and surgical treatment of severe colitis
and attendant complications, related to patient-orientated
outcomes (hospitalization, time off work, colectomy and
mortality) are still required.
5.2.7. Refractory proctitis and distal colitis
Refractory proctitis and distal colitis present common
clinical dilemmas.94,95 There are few trials on this specific
population, but a coherent therapeutic strategy is needed if
patients (and their doctors) are not to get frustrated by
persistent symptoms.
Reasons for refractoriness include poor adherence with
therapy, inadequate concentrations of the active drug, the
wrong drug, unrecognised complications (such as proximal
constipation or infection) or inappropriate diagnosis (such as
co-existent irritable bowel syndrome, unrecognised infec-
tion, Crohn's, mucosal prolapse, or very rarely, cancer). The
first step is therefore an empathetic review of symptoms and
treatment to date, followed by reassessment of the diagnosis
by colonoscopy and serial biopsy. Commonly, a co-existent
irritable bowel accounts for more symptoms than active
disease. The next step is to ensure that conventional thera-
py (Sections 1.2.1 and 1.2.2) has been vigorously applied.
Attention in particular should be paid to topical therapy
(topical mesalazine together with topical steroids, after
considering suppositories and the type of enema for the
distribution of disease) in conjunction with oral therapy. The
next step is to treat proximal constipation, since abnormal
intestinal motility induces proximal colonic stasis in patients
with distal colitis and this affects drug delivery. In 12 patients
with active left-sided disease, scintigraphy showed that 91%
of a labelled, Eudragit-coated resin remained in the proximal
colon, so that only 9% (95%CI 4–15) reached the distal co-
lon compared to 31% (95%CI 24–37) in 22 healthy controls
(pb0.001).96 Consequently, if sigmoidoscopic inflammation
persists after treatment with topical mesalazine and oral
steroids, a plain abdominal radiograph is appropriate. If
there is visible faecal loading in the descending colon, a
vigorous laxative is appropriate, after explaining the paradox
of proximal constipation despite distal diarrhoea. If symp-
toms do not resolve within another 2–4 weeks, distal colitis is
best treated as if it was more extensive or severe.
Refractory distal colitis respondsmore rapidly and better to
intensive treatment than oral or topical therapies. In
39 patients with distal disease refractory to outpatient
treatment with oral steroids and mesalazine, remission was
achieved by intensive treatment within a week in 90%.97
Should the response be poor, CsA, tacrolimus, or IFX can be
tried, but only if there is a prospect for maintaining remission.
There is a tendency to opt for these treatments before
admission for intensive therapy, with a view to continuing
treatment as an outpatient. 56% in the ACT 1&2 studies had
left-sided or distal colitis. However, the patient must realise
that the steroid-free remission rate after 7 months (30 weeks)
on IFX is only 21%78 (see also Section 5.3.3). If disease persists
in spite of these approaches, surgery is likely to be the
outcome, but if the patient is not acutely ill then the decision
should never be precipitate and a range of topical or anecdotal
ECCO statement 5H
Patients with persistently active, steroid-refractory
disease should be treated with azathioprine/mer-
captopurine [EL1b, RG B], although surgical options
should also be considered and discussed. Intrave-
nous steroids, infliximab [EL1b, RG B] or calcineurin
32 S.P.L. Travis et al.therapies are available (Table 5.2).98–134. The choice depends
on local availability and personal preference, since many have
to be made up individually by pharmacy. Clinical judgement
and an honest appraisal about the impact of symptoms on the
quality of life or employment are necessary.
Up to 10% of patients who have a colectomy for refractory
UC only have distal disease. A total colectomy has to be
performed, usually with ileoanal pouch formation (Section
7.2), because segmental resection leaves that part of the
colon most affected and is almost invariably followed by
relapse affecting previously normal bowel. The outcome of
colectomy and pouch formation for distal colitis is usually
good. In 263 patients who had a restorative proctocolectomy
at one French centre (1986–96), 27 had surgery for distal
disease.135 There was a significant decrease after surgery in
mean (SD) diurnal stool frequency (8.2(4) vs 4.7 (2) pb0.05),
nocturnal stool frequency and urgency (pb0.001). Previously
unknown severe dysplasia was identified in 2 patients. All but
one patient were satisfied with the results and 25/27 wished
that they had had surgery sooner.
5.3. Treatment according to the course or
behaviour of disease
Treatment decisions differ between patients at initial pre-
sentation and subsequent relapse, depending on the pattern
of relapse and previous response to therapy. Some patients
have active disease that persists in spite of appropriate
treatment and these are best considered as a separate
group with steroid-refractory disease (see definitions). It
helps management to recognise other treatment-refractory
groups (immunomodulator-refractory, or anti-TNF-refrac-
tory), but precise definitions have not been agreed (Section
5.2). They represent an important group of patients who
merit study.
5.3.1. Treatment of relapse compared to new casesinhibitors [EL3, RG C] should also be considered
ECCO statement 5G
Patients who relapse should usually be treated
with the therapy that was previously effective
[EL5, RG D]The initial treatment of relapse best uses the treatment
that worked first time, but consideration should be given to
other factors and maintenance therapy should be optimised.
These include the views of the patient (adverse effects,
necessary speed of response, convenience, etc), timing of
relapse, concurrent therapy (whether a relapse occurred
during treatment with immunomodulators) and adherence
with maintenance therapy.
5.3.2. Early relapse
Any patient who has an early (b3 months) relapse is best
started on azathioprine (AZA) or mercaptopurine (MP),
because the treatment strategy should think beyond the
current relapse and aim to reduce the risk of a further
relapse. Opinion is divided whether to use the same treat-
ment to induce remission and taper more slowly, use morepotent induction therapy, or to increase maintenance ther-
apy. It is generally unnecessary to re-evaluate the distribu-
tion of disease unless this will influence medical or surgical
management. Continued medical therapy that does not
achieve steroid-free remission is not recommended.
5.3.3. ‘Steroid-dependent’, active ulcerative colitis
Azathioprine is significantly more effective than mesalazine
at inducing clinical and endoscopic remission in
the treatment of steroid-dependent UC. 72 patients with
steroid-dependent, active UC were randomised to receive
AZA 2 mg/kg/day or oral mesalazine 3.2 g/day, in addition
to prednisolone 40 mg/day.136 53% on AZA achieved steroid-
free clinical and endoscopic remission after 6 months
compared to 21% on mesalazine (OR 4.78, 95%CI 1.57–
14.5). Infliximab also has a steroid-sparing effect when
administered every 8 weeks for up to 1 year.78. 408/728
(56%) were taking steroids at study entry in the two ACT
studies. After 7 months (30 weeks), 10/139 (7%) on placebo
and 28/130 (21%) on 5mg/kg IFX every 8 weeks had achieved
steroid-free remission (p=0.01). After 12 months (ACT 1),
the figures were 9% and 26% respectively (p=0.006) (Section
5.3.4). AZA should be the first choice of therapy in apparent
steroid dependence. The balance in decision-making
between IFX and surgery is addressed above (Sections
1.2.3, 1.2.4) and the efficacy of continued AZA or IFX for
maintaining remission in Sections 2.2.2 and 2.2.3.
5.3.4. Oral steroid-refractory ulcerative colitisFor active UC that is refractory to steroids, other causes
of persistent symptoms including coexistent cytomeg-
alovirus, or cancer should be considered. If active UC is
confirmed, immunomodulators should be added and cal-
cineurin inhibitors, biological therapy or surgery consid-
ered (Section 5.2.5, 5.4.3). Infliximab is indicated if sepsis
has been excluded and surgery thought inappropriate at
that stage. The timing of surgery depends on the severity
of symptoms, inflammatory burden and other considera-
tions (Sections 1.2.4, 1.2.5, 1.4.3). The patient's gender,
age, fecundity and extent of disease should be taken into
account. The sequence (or hierarchy) of therapy has to
depend on the individual circumstances and views of the
patient.
5.3.5. Immunomodulator-refractory ulcerative colitis
Immunomodulator-refractory disease is also best reassessed
by colonoscopy and biopsy to confirm the diagnosis and
exclude complications. A therapeutic strategy that includes
consideration of how steroid-free remission will be achieved
and maintained should be discussed with the patient. In the
Table 5.2 Summary of therapies for distal colitis
Agent Proposed mechanism Dose and duration Design n Outcome Ref
Anaesthetic gel Neuroimmune modulation Lignocaine (800 mg) daily. 6–34 weeks Open 100 Remission 10% proctitis, 83% distal colitis.
Most had refractory disease; response in
6 patients with pancolitis
99
Lignocaine (600 mg) daily. 6 weeks Open 22 12/22 ‘excellent’, 4/22 ‘very good’ response
(refractory UC)
100
Ropivacaine (400 mg) daily. 2 weeks Open 12 Clinical and endoscopic improvement
(pb0.05)
101
Ropivacaine (200 mg) single dose Random 33 Rectal eicosanoid & neuropeptide
concentrations similar after ropivacaine
in 19 distal UC compared to 14 controls
102
Appendicectomy Altered Th1/Th2 balance Surgery Cases 16 Remission, with no recurrence for up to
3years
103
Arsenic Uncertain Acetarsol (500 mg) vs prednisolone (5 mg)
suppositories. 2 weeks
Random 20 9/10 clinical/endoscopic improvement
(refractory distal colitis). Potential toxicity
in 6/10 (1 week) 2/10 (4 weeks)
104
Bismuth compounds Enhanced mucosal barrier?
Reduced bacterial adhesion
Bismuth carbomer (450 mg) enema vs
5-ASA (2 g) enema. 4 weeks
Random 63 Bismuth 39% remission, 56% 5-ASA (p=0.16) 105
Bovine colostrum Source of growth factors for
epithelial restitution
Colostrum 10% (100 mL enema) vs placebo
(albumin) 4 weeks
Random 14 Activity index −2.9 (−0.3 to −5.4) in
colostrum group, vs +0.5 (−2.4 to +3.4)
in placebo
106
Ciclosporin enemas T-cell immunosuppression Cyclosporin 350 mg vs placebo. 4 weeks Random 40 Cyclosporin 40% improvement vs placebo
45%. Open trials in refractory distal UC
more favourable
107
Epidermal growth
factor enemas
Epithelial restitution/repair EGF 5mcg (100 mL enema) vs placebo.
12 weeks
Random 24 83% remission at 4 weeks vs 8% on placebo.
Rapid and promising; needs repeating.
Concern about malignancy
108
Ecabet sodium
enema
Mucosal protection Ecabet sodium 1 g in 20–50 mL. 2 weeks Open 8 Clinical activity index decreased
(5.3+1.4 to 0.5+0.8, pb0.05)
109
Immunoglobulin G
enemas
Immune response promoter IgG enema Open 7 Ineffective. 1/7 improved. 110
Interleukin-10
enemas
? IL-10 deficiency in UC IL-10 100mcg enema for 10 days Open 3 Endoscopic response in refractory
left-sided colitis
111
Leukocytapheresis ?monocyte adsorption Weekly for 5 weeks Open 30 Clinical remission 21/30 112
Nicotine Smoking protective. Transdermal nicotine (15–25 mg) vs
placebo 6 weeks
Random 72 Nicotine 48% remission, placebo 24%
(p=0.03)
113
Transdermal nicotine vs placebo. 6 m Random 80 No difference between groups for
maintenance therapy
114
Transdermal nicotine (15–25 mg) vs
prednisolone (5–15 mg). 6 weeks
Random 61 Nicotine 21% remission vs 47% prednisolone
(p=0.035), intention to treat. 11/31
nicotine withdrawals (side-effects)
115
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Table 5.2 (continued)
Agent Proposed mechanism Dose and duration Design n Outcome Ref
Nicotine Smoking protective. Transdermal nicotine vs placebo. 4weeks Random 64 Nicotine 39% clinical response, placebo
9% (p=0.007)
116
Transdermal nicotine (15 mg) with 5ASA
enema vs enema+mesalazine
2.4 g. 4 weeks
Random 30 Remission 12/15 on nicotine+5ASA enema,
5/15 on oral 5ASA+enema (p=0.027)
117
Nicotine tartrate enemas (3–6 mg). 4 weeks Open 10 5/7 improved (previously unresponsive UC).
3 withdrawals
118
Nicotine carbomer enemas (6 mg). 4 weeks Open 22 16/17 improved (previously unresponsive).
6 withdrawals
119
Propionyl-
L-carnitine
(PLC) enemas
Epithelial (SCFA) nutrition PLC 6 g (200 mL) twice daily. Open 10 8/10 ‘improved significantly’ 120
Rebamipide Cytoprotective proprionic
acid
Enema twice daily, oral steroids continued Open 20 55% remission 9still on steroids) at 3 weeks 121
Short chain fatty
acids (variable
composition)
Epithelial nutrition SCFA mixture vs 5-ASA or steroid enema.
6 weeks
Random 45 Most improved in all three groups 122
SCFA mixture vs placebo. 6 weeks Random 40 70% SCFA clinical response, 20% placebo
No change in endoscopic or histology scores
123
SCFA mixture. 6 weeks Open 10 5/10 responded well (refractory distal
colitis)
124
SCFA mixture vs placebo. 6 weeks Random 103 No difference in clinical or histological
response
125
SCFA vs butyrate or placebo. 6 weeks Random 47 No difference between three groups 126
Butyrate vs placebo. 6 weeks Random 38 No difference 127
Sucralfate Enhanced mucosal barrier Sucralfate 4 g vs prednisolone meta-
sulphobenzoate 20 mg enemas. 4 weeks
Random 44 Predenema 71% cessation of bleeding,
sucralfate 28%
128
Sucralfate 10 g vs 5-ASA 2 g vs placebo
4 weeks
Random 50 5-ASA superior. Sucralfate no different
from placebo
129
Sucralfate 10 g vs hydrocortisone 100 mg
enemas. 4 weeks
Random 40 Hydrocortisone 42% remission, sucralfate
15%, (pb0.05)
130
Sucralfate 20 g vs methylprednisolone 20 mg
(100 mL) twice daily. 4 weeks.
Random 60 No difference between groups 131
Thromboxane A2
inhibitor
Inhibition of inflammatory
mediator
Ridrogel 300 mg vs prednisolone 30 mg enemas.
4 weeks
Random 40 Ridrogel 65% endoscopic remission vs prednisolone
75%
(no difference)
132
Ridogrel 300 mg (40 mL) Open 11 Decrease in mucosal TxB2, but not
other PGs
133
Wheat grass juice Prebiotic and antioxidant
Triticum aestivum
WGJ (100 mL) vs placebo Random 21 Decrease in activity index (p=0.031)
and rectal bleeding (p=0.025)
compared to controls
134
34
S.P.L.
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et
al.
ECCO statement 5I
Infliximab [EL1b, RG B] or surgical options should
be considered. Continued medical therapy that
does not achieve steroid-free remission is not
recommended [EL5, RG D]
35ECCO Consensus on UC: Current managementabsence of contraindications infliximab should be considered
(Section 5.4.3) as well as colectomy, which may be most
appropriate.
5.4. Therapy-specific considerations
The therapeutic goal should be to induce steroid-free clinical
remission, but it is essential to keep in mind how remission
will be maintained (Section 6). The treatment strategy
depends primarily on the activity and distribution of UC
(Section 5.2); the current section considers drug-specific
aspects of treatment not addressed in that section.
5.4.1. Aminosalicylates
5.4.1.1. Efficacy of aminosalicylates. Much is made of
how different delivery systems may influence response, but
evidence that it matters in clinical practice is remarkably
thin. Delivery systems can be divided into azo-compounds,
controlled release, pH-dependent (either pH6 or pH7) and
composite (pH-dependent combined with controlled release)
(Table 5.3137–139).
Systematic reviews and meta-analyses concur that amino-
salicylates are effective for treating active UC.21,22,27 The NNTTable 5.3 Delivery systems for 5-ASA137,138
Delivery system
Azo-bond
Sulfasalazine Sulfapyridine carrier
Olsalazine 5-ASA dimmer
Balsalazide 4-amino-benzoyl-β-alanine
Controlled release
Pentasa® Ethylcellulose coated microg
pH7-dependent
Asacol® Eudragit-S coating, dissolves
Mesren® Same
Ipocol® Same
pH6-dependent
Salofalk® Eudragit-L coating, dissolves
Mesasal® Same
Claversal® Same
Composite
(‘multimatrix’)Mezavant® (EU)
Lialda® (US)
Eudragit-S coating of hydrop
with some 5ASA and lipophili
encapsulating 5ASAto induce remission is 10 (95%CI 7–21), although for the lesser
target of response or remission the NNT is 4 (95%CI 3–6)22).
Available data do not suggest a difference in efficacy between
any of the 5-ASA preparations for active UC. Six trials with
mesalazine (including two trials on MMX mesalazine) show
statistical significance vs placebo.23, 24,140–142,147 Those with
olsalazine143–146 or balsalazide [unpublished, see ref 27] do not.
Mesalazine is shown to be as effective as sulfasalazine for
inducing response or remission (OR 0.83, 95%CI 0.60–1.1321)
in the most recent meta-analysis, and is better tolerated.
There have been few clinical trials comparing the efficacy of
newer aminosalicylates for inducing remission. In 2 of 3 trials
of balsalazide vs mesalazine, results for defined primary and
secondary endpoints failed to demonstrate statistically sig-
nificant differences.148–150 Another study compared Ipocol, a
pH7-dependent release mesalazine, with Asacol and found
no significant difference in remission rates after 2.4 g/d for
8 weeks.151 Proprietary prescribing of mesalazine is recom-
mended,152 but for active UC the choice of 5ASA cannot be
made on the grounds of efficacy alone. The route of delivery,
dose frequency, cost and availability are more relevant
factors in the choice.
5.4.1.2. Adverse effects of aminosalicylates. Mesalazine
has a topical action on colonic epithelial cells, where it is
also metabolised. Systemic exposure is therefore unneces-
sary. This means that drug efficacy cannot be deduced from
pharmacokinetic comparisons, but absorption might con-
ceivably influence adverse events. Despite variable differ-
ences in peak serum concentrations, ratio of 5ASA to its
metabolite N-acetyl 5ASA, however, the systemic exposure
to equimolar doses of all 5-ASA compounds is similarMean peak plasma
[5ASA] (μmol/L)
Mean systemic
exposure
(AUC, μmol/L.h)
0.7–3.5 9.6–27.5
1.2–4.5 –
2.3–3.5 13.9–22.8
ranules 6.5 28.5
at pH7 2.1–10.5 21.5–25.1
– –
– –
at pH6 10.9 38.3
5.2 (median) 21.5 (median)
–
hilic polymer
c excipients
– no published data
Table 5.4 Placebo-controlled trials of newer aminosalicylates for active UC
n Dose, g (n) Weeks Remission (unless otherwise stated) Ref
Asacol®
Schroeder 1987 87 4.8 (38), 1.6 (11), 0 (36) 6 24% vs 5% (4.8 vs 0, p=0.047) 140
Sninsky 1991 158 2.4 (53), 1.6 (53), 0 (52) 6 Response 49% vs 23% (2.4 vs 0, p=0.004) 141
Balsalazide
Salix (unpublished) 180 6.75 (72), 4.5 (73), 0 (35) 4 Response 45% vs 45% (6.75 vs 0, ns) 27
MMx mesalazine
Lichtenstein 2007 280 4.8 g×1 (94), 1.2 g×2 (93), 0 (93) 8 29% vs 13% (4.8 g×1 vs 0, p=0.009) 23
Kamm 2007 343 4.8 g×1 (85), 2.4 g×1 (84), 0 (86)
Asacol 0.8g×3 (86)
8 41.2% vs 40.5% vs 22.1% vs 32.6%
(4.8g×1 vs 0, p=0.007)
24
Pentasa®
Hanauer 1993 374 4 (95), 2 (97), 1 (92), 0 (90) 8 29% vs 12% ( 4g vs 0, p=0.0012) 142
Olsalazine
Meyers 1987 66 3 (15), 1.5 (16), 0.75 (15), 0 (20) 3 Improvement 50% vs 16% (3 vs 0, p=0.055) 143
Hetzel 1988 30 2 (15), 0 (15) 8 Improvement 40% vs 11% (p=0.11) 144
Feurle 1989 105 2 (52), 0 (53) 4 Improvement (ns, no absolute numbers) 145
Zinberg 1990 15 3 (7), 0 (8) 4 Improvement (4/7 vs 0/8, pb0.05) 146
Rowasa®
Sutherland 1990 136 4 (47), 2 (45), 0 (44) 6 Improvement 45% vs 18% (4 vs 0, pb0.05) 147
36 S.P.L. Travis et al.(Table 5.4). Mesalazine intolerance occurs in up to 15%.
Diarrhoea (3%), headache (2%), nausea (2%), rash (1%) and
thrombocytopenia (b1%) are reported, but a systematic review
has confirmed that all new 5-ASA agents are safe, with adverse
events that are similar to placebo for mesalazine or olsala-
zine.153 Acute intolerance in 3%may resemble a flare of colitis
since it includes bloody diarrhoea. Recurrence on rechallenge
provides the clue. Renal impairment (including interstitial
nephritis and nephrotic syndrome) is rare and idiosyncratic. A
population-based study found the risk (OR 1.60, CI 1.14–2.26
compared to normal) to be associated with disease severity
rather than the dose or type of mesalazine.154
5.4.1.3. Monitoring. Patients with pre-existing renal im-
pairment, other potentially nephrotoxic drugs, or co-
morbid disease should have renal function monitored
during 5-ASA therapy. Many clinicians believe that creati-
nine and full blood count should be monitored every 3–
6 months during aminosalicylate therapy, although there is
no evidence favouring one monitoring regime over another.
5.4.2. Corticosteroids
5.4.2.1. Efficacy of steroids. There have been only two
placebo controlled trials of conventional oral steroids for
outpatientswith active UC,29,155 giving anNNTof 2 (95%CI 1.4–
5).22 More recently, when 86 (out of a total of 136) newly
diagnosed patients with UC were treated with steroids, 51%,
31% and 18% had a complete response, partial or no response
respectively at 30 days.156 However, this includes a group of
22/86 who had acute severe colitis needing intravenous
treatment. At one year, 55% were in steroid-free remission,
17% were steroid-dependent, 21% had surgery and 7% lost
to follow up, but the inclusion of severe colitis makes thisdifficult to extrapolate to outpatient therapy. Adverse effects
andmonitoring of steroid therapy are the same as described in
the Consensus guidelines on Crohn's disease.157
5.4.3. Infliximab (IFX)
5.4.3.1. Efficacy of IFX. A systematic review of the efficacy
of IFX for treating patients with moderate to severe UC
refractory to corticosteroids and/or immunomodulators, con-
cluded that it was effective for inducing clinical remission,
clinical response, promoting mucosal healing, and reducing
the need for colectomy in the short term.158 The review took
the description of ‘severe’ at face value and failed to discri-
minate between out-patients and in-patients with acute
severe colitis. Nevertheless, in seven RCTs, IFX (three
intravenous infusions at 0, 2, and 6 weeks) was more effective
than placebo in inducing clinical remission (RR 3.22, 95%CI
2.18–4.76). Itwas alsomoreeffective thanplacebo at inducing
endoscopic remission (RR 1.88, 95%CI 1.54–2.28) and clinical
response (RR 1.99, 95% CI 1.65–2.41) at 8 weeks.78,159–162 A
single infusion of infliximab was also more effective than
placebo in reducing the need for colectomy within 90 days
after infusion (RR 0.44, 95%CI 0.22–0.87).73 The ACT 1&2
studies are pivotal.78 They are impressively consistent,
showing double the remission rate compared to placebo. ACT
1was a 364 patient study inmoderately activeUC refractory to
oral steroids and/or thiopurines, given IFX 5 mg/kg, 10 mg/kg,
or placebo at 0, 2 and 6 weeks, then every 8 weeks for a year.
The primary endpoint at week 8 was response (N30% and a 3
point decrease in the Mayo activity index, with virtual
cessation of rectal bleeding). This was achieved: 37.2%
(placebo), 69.4% (5 mg/kg) and 61.5% (10 mg/kg), pb0.001).
So too were pre-defined secondary endpoints of remission
(14.9%, 38.8% and 32.0% respectively) and mucosal healing
37ECCO Consensus on UC: Current management(33.9%, 62.0%, and 59.0%). Duration of effect was maintained
through week 30 in all respects (remission in 15.7%, 33.9% and
36.9%, pb0.001). The same goes for ACT 2, an almost identical
trial of a further 364 patients, but who could have moderately
active UC despite 5-ASA alone (26%) and was 6 months'
duration. Response (and remission) rates at week 8were 29.3%
(5.7%, placebo), 64.5% (33.9%, 5 mg/kg) and 69.2% (27.5%,
10 mg/kg, pb0.001). The flat dose-response is comparable to
that of IFX for Crohn's disease.157 Unfortunately, a large
therapeutic gap persists despite being on 5 mg/kg IFX every
8weeks, becauseonly21% (at 7months) and26% (at 12months)
achieved steroid-free remission (see Section 5.3.3). This is
important because the Consensus stresses the importance of
achieving steroid-free remission. Further analysis of the ACT 1
& 2 trial data indicates that there was an associated reduction
in colectomy (hazard ratio 0.57, 95% CI 0.37–0.89) during the
trial,165 but whether this benefit is maintained remains
unclear.The actual role of IFX for UC refractory to conventional
therapy for both outpatients and inpatients is discussed in
Sections 1.2.5, 1.2.7, 1.3.3, 1.3.4 and 1.3.5.
5.4.3.2. Adverse effects of IFX. Treatment with IFX is
relatively safe if used for appropriate indications. Adverse
events in the ACTstudies78were nodifferent to those expected
from large experience of treating Crohn's disease.163,164
Nevertheless, in common with other biological therapy there
is a risk of serious infection, demyelinating disease and
associated mortality. In the combined analysis of 484 patients
with UC who received IFX in the ACT trials there were 8 who
developed pneumonia, 1 tuberculosis and 1 histoplasmosis
(who later died) as well as 4 neoplasia (all probably pre-
existing, but presenting in the trial period) and 3 neuropathies
(2 optic neuritis, 1 multifocal motor), equivalent to 3.5% (17/
484). By contrast, in the 244 who received placebo there was
just 1 basal cell carcinoma. Prolonged medical therapy for a
potentially pre-malignant condition with anti-tumor necrosis
factor therapy creates its own anxieties. Tighter surveillance
to detect dysplasia may be necessary, although no evidence-
based recommendations can currently be given.
5.4.4. Other biological therapy
Despite the proliferation of biological therapies, only few have
been applied to UC.Adalimumab is an anti-TNF agent similar to
IFX, but given subcutaneously with less immunogenicity. There
are current trials in UC. Visilizumab is an anti-CD3 monoclonal
antibody binding to activated T-cells to induce apoptosis. A
dose-ranging study in 69 patients with severe, intravenous
steroid-resistant UC showed a 30 day remission rate of 30% (60%
response) to 5microg/kg given on two consecutive days.166 A
Phase III study in intravenous steroid-resistantUC, however,was
suspended in Q307 when interim analysis showed no benefit.
Alicaforsen is an anti-sense oligonucleotide to human ICAM1.
A complex dose-ranging protocol in 112 patients showed that a
240 mg enema every night for 6 weeks was more effective than
placebo. Remission was only 14% at 6 weeks, but response was
then maintained for 6 months in 80% compared to 44% on
placebo,167 or a median 146 days compared to 54 days after
mesalamine enemas in another study.168 Another selective anti-
adhesionmolecule strategy is also effective for UC. Intravenous
MLN-02 (an α4β7 integrin antagonist) was given to 181 patients
withmoderately activeUC.169 Clinical remission rates atweek 6
were 33% and 32% for 0.5 mg and 2.0 mg/kg respectively,compared to 14% on placebo (p=0.03). Although one IL-2
receptor (CD25) inhibitor, basiliximab, has shown potential in
open studies for steroid-refractory UC170 another CD25 inhi-
bitor, daclizumab, was ineffective in a controlled trial of 159
patients with moderately active UC.171 Certolizumab has not
yet beenevaluated forUC.172 AnAmerican–European reviewon
biological therapy for UC has been published.173
5.4.5. Thiopurines
5.4.5.1. Efficacy of azathioprine/mercaptopurine. Data
on thiopurines for active UC are few.167 There have been five
placebo-controlled trials of AZA for active UC, of between
20 and 80 patients each, with differing entry criteria, dose and
duration.136,174–178 Data from a recent, well conducted study
on steroid-dependent active UC131 are discussed in Section
5.3.3. The main role for thiopurines are as steroid sparing
agents (NNT 3). Immunomodulators should be started in
steroid-dependent or steroid-refractory patients. For arbitrary
but practical purposes, thiopurines are considered appropriate
for the same indications as for Crohn's disease: patients who
have a severe relapse; thosewho require two ormore corticos-
teroid courses within a 12 month period; those whose disease
relapses as the dose of steroid is reduced below an arbitrary
15 mg; and relapse within 3 months of stopping steroids.158
There is some evidence from a retrospectivemulticentre study
of 1176 patients that those on AZA for UC are more likely to
relapse if it is discontinued after 4 years than are patients who
have Crohn's disease.179
5.4.5.2. Dose,monitoring andadverse effects of thiopurines.
All aspects are considered similar to the use of thiopurines for
Crohn's disease.158 More recent work on measuring thiopurine
methyl transferase (TPMT) and ITPA genotypes, TPMT activity,
TPMT gene expression and thiopurinemetabolites, is consistent
with previous reports that the development of different types
of toxicity is unpredictable.180 This prospective study on 60
patients (27 with UC) study did, however, find that measure-
ment of meTIMP early in the steady state phase might identify
patients at risk of developing myelotoxicity. No recommen-
dation can be made about routine measurement of TPMT
activity or genotype prior to initiating thiopurine therapy,
althoughall agree thatmonitoring of the full blood count before
and after starting therapy is appropriate.
5.4.6. Methotrexate (MTX)
5.4.6.1. Efficacy of MTX. Studies on MTX for UC are
small, use varying doses or routes of administration and
have inconsistent outcomes.181–183 The only randomised
placebo-controlled trial using a dose of 12.5 mg per week
of oral MTX in UC showed no benefit.181 The low dose may
account for disappointing efficacy as well as the lack of
side effects. A randomized comparison of oral MTX 15 mg/
week (still a relatively low dose) with mercaptopurine (MP)
1.5 mg/kg/day and 3 g/day 5-ASA for 72 steroid-dependent
patients (34 UC and 39 Crohn's) showed a remission rate at
30 weeks of 79% for MP, 58% for MTX 25% for 5-ASA (pb0.05
vs MP, ns vs MTX).182 This is the only published comparison
of MP and MTX. Until more data are available it cannot
generally be considered an alternative to thiopurines for
steroid-resistant UC (see also Section 6.2.5).
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As with thiopurines, all aspects are considered similar to
Crohn's disease, for which evidence from controlled trials
supports its use.158,184
5.4.7. Calcineurin inhibitors (ciclosporin (CsA)
and tacrolimus)
5.4.7.1. Efficacy of CsA. Details of the role of CsA and
tacrolimus for severe UC are given in Sections 1.2.4 and 1.2.5.
5.4.7.2. Dose and monitoring. Low dose CsA (2 mg/kg iv)
induction therapy has largely addressed concerns about early
toxicity. In the largest randomized study of CsA to date, 73
patients were randomized to either 2 mg/kg or 4 mg/kg of
intravenous CsA.50 Response rates at 8 days were similar in
both groups (86% and 84% respectively), with 9% coming to
colectomy in the 2 mg/kg group and 13% in the 4 mg/kg
group. The study was too small to show a difference in
serious side effects, but there was less hypertension in the
lower dose group. The majority of CsA side-effects are dose-
dependent. At the 2 mg/kg dose, the mean CsA concentra-
tion on day 4 was 246+64 ng/mL, but 345+146 ng/ml with
the 4 mg/kg dose. Suitable target levels to induce remission
are not known, but in responders on oral medication, whole-
blood trough levels of 100–200 ng/ml using a monoclonal
radioimmunoassay are generally considered satisfactory. It
is said that 2 h post-dose peak levels give the best esti-
mate of drug exposure by correlating with the pharmacoki-
netic area under the curve185 and an appropriate target
appears to be 700 ng/mL, but this has not been correlated
with efficacy for UC.
Tacrolimus is more effective when given at a dose that
achieves a trough concentration of 10-15 ng/m.67 The initial
oral dose in this randomized trial of 60 steroid-refractory
patients with active UC was 0.05 mg/kg/day, increased ac-
cording to the trough level after 24 hr. 13 (68%) achieving this
trough level responded within 2 weeks, compared to 8 (38%)
achieving a lower trough level and 2 (10%) in the placebo
group. None had a complete response. Oral dosing may be an
alternative to intravenous administration but only retro-
spective data are available.70
In practice, either calcineurin inhibitor appears able to
induce remission, although whether either alter the long-
term pattern of disease is unknown. First principles indicate
that treatment is best continued until immunomodulator
therapy (AZA/MP/MTX) is established. Although this reduces
the short-term colectomy rate, the risk of clinical relapse
remains high in the first year after treatment63–65 (see
Section 6.2.2).
5.4.7.3. Adverse effects of calcineurin inhibitors. Hyper-
tension, paraesthesiae or tremor and headache are the com-
monest adverse events. Hypomagnesaemia, renal
impairment, or gastrointestinal upset affect around half of
patients.67 Tacrolimus may induce diabetes mellitus. Oppor-
tunistic infection is the main concern; 3/86 patients (3.5%)
died of opportunistic infections (1 of Pneumocystis jiroveci
(carinii) pneumonia and 2 of Aspergillus fumigatus pneumo-
nia) in a series from a major specialist centre.186 Opportu-
nistic infections and the value of chemoprophylaxis is the
topic of a separate ECCO Consensus.5.4.8. Alternative therapies whose role remains to
be established
5.4.8.1. Antibiotics. Antibiotics as an adjunct to steroids do
not alter the outcome of severe colitis (Section 5.2.4,43–48),
but treatment of refractory colitis UC associated with Fuso-
bacterium varium has been reported.187 Two weeks' triple
therapy with amoxicillin 500 mg, tetracycline 500 mg and
metronidazole 250 mg all three times daily improved clinical,
endoscopic and histological scores in a randomised trial of 20
patients.187 More evidence is needed.
5.4.8.2. Helminths. Observations that there is an epide-
miological mismatch between UC and helminth infections,
together with experimental evidence that several helminths
moderate immune-mediated models of colitis lead to ther-
apeutic trials of Trichuris suis ova. T suis, the pig whipworm,
transiently colonises the gut, but is non-pathogenic in man.
In a randomised trial of 54 patients with mild-moderately
active UC, 3/30 of those treated with 2500 T suis ova every
2 weeks for 12 weeks achieved remission compared to 1/24
given placebo (ns), with a response in 43% and 17% re-
spectively (p=0.04).188 The optimal dose, interval and du-
ration of treatment need to be established and the response
confirmed in a larger study.
5.4.8.3. Heparin. Heparin promotes epithelial restitution
and repair in addition to anticoagulant properties. Out of two
small controlled trials of unfractionated heparin and three
using low molecular weight heparin in up to 100 patients,
only the smallest trial has shown benefit for active UC.189 It
cannot currently be recommended, although novel delivery
systems are being developed.
5.4.8.4. Interferon-alpha. Interferon alpha induces anti-
inflammatory cytokines ((IL-1RA, among others) and down
regulates IL-13, giving it a potential role in the treatment of
active UC. A trial of 60 patients randomised to weekly
injections of pegylated interferon alpha at 1.0 mcg/kg,
0.5 mcg/kg, or placebo for 12 weeks showed no consistent
differences between the groups.190
5.4.8.5. Leucocytapheresis. Leucocytapheresis involves
extracorporeal removal of leucocytes through an adsorptive
system of cellulose acetate beads (Adacolumn®, Otsuka
Pharmaceuticals), or a polyester fibre filter (Cellsorba®,
Asahi Medical Company). The former removes 65% of
neutrophils, 55% monocytes, and 2% lymphocytes while the
latter removes up to 100% of neutrophils and monocytes, and
20-60% lymphocytes. Sessions last an hour, during which
time 2–3 l of blood is drawn from one arm, filtered, and
infused into the other arm. A course of treatment is typically
5–10 sessions at intervals of 1–2/week. There have been a
multiplicity of observational studies, two unusually designed
randomised trials comparing leucocytapheresis with predni-
solone191 or a sham column,192 and one large trial comparing
it with sham apheresis for active UC that has yet to report. It
appears that leucocytapheresis does something for active
UC, but quite what and how much is difficult to define.193 It
has wide-spread acceptance in Japan. Expense may limit its
use, but the outcome of controlled trials will govern its
future role in Europe.
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active disease
A patient's response to initial therapy should be assessed
within several weeks. If treatment is effective, the patient
should continue until symptomatic remission is achieved or
further improvement ceases. An outcome other than
steroid-free remission after treatment of active disease is
considered unacceptable, whether or not immunomodula-
tors or biological therapy is used. Maintenance therapy is
recommended after successful medical treatment of active
disease.
6. Maintenance of remission
6.1. General
6.1.1. Maintenance therapy trial design
Most trials of maintenance therapy for UC have enrolled
patients in clinical and endoscopic remission. In such studies,
steroids are typically not permitted as concomitant therapy.
The endpoint is the absence of relapse (or failure to maintain
clinical remission) after 6 or 12 months.2 Clinical relapse is
defined by an increase in stool frequency and recurrence of
rectal bleeding, confirmed by endoscopy (Section 1.1.5). This
approach to the evaluation of maintenance therapy is not
cast in stone, because in two recent studies, both induction
and subsequent maintenance therapy were assessed in the
same trial of infliximab.78 Using this approach, the clinical
response at week 8 was defined as the primary endpoint, and
the efficacy of maintenance therapy evaluated by the
secondary endpoints of clinical response, clinical remission
and mucosal healing at weeks 30 and 54 (Section 6.2.3). The
pivotal endpoint that matters to patients is clinical remission
with complete corticosteroid discontinuation in those who
were receiving steroids at baseline.ECCO statement 6A
The goal of maintenance therapy in UC is to main-
tain steroid-free remission, clinically [EL1, RG A]
and endoscopically defined [EL2, RG B] ECCO statement 6C
Choice of maintenance treatment in UC is deter-
mined by disease extent [EL1b, RG B], disease
course (frequency of flares) [EL5, RG D], failure of
previous maintenance treatment [EL5, RG D],
severity of the most recent flare [EL5, RG D],
treatment used for inducing remission during the
most recent flare [EL5, RG D], safety of main-
tenance treatment [EL1b, RG B], and cancer
prevention [EL2a, RG B]6.1.2. Pattern of disease
More than half of patients with UC have a relapse in the year
following a flare. In clinical trials designed for the main-
tenance of remission in patients with clinical remission at
baseline, clinical relapse rates among patients receiving
placebo range from 29% to 43% at 6 months, and from 38% to
76% at 12 months.2,9,194 A population-based study carried out
in the county of Copenhagen,195 described the outcome
in1575 patients in the first 5 years following diagnosis ofECCO statement 6B
Maintenance treatment is recommended for all
patients [EL1a, RG A]. Intermittent therapy is
acceptable in a few patients with disease of
limited extent [EL5, RG D]UC between 1962 and 2005. In the most recent period, the
percentage of patients experiencing an ‘indolent’ course (no
relapse during the first 5 years after diagnosis) was 13%, while
74% had ‘moderate’ course (two or more relapses within the
first 5 years, but less than every year), and 13% had an
‘aggressive’ course (disease activity at least every year
during the first 5 years). This highlights using the term
‘moderate’ to refer sometimes to the pattern of disease and
also to the activity at a point in time, which can be the source
of confusion (Sections 5.1.2, 1.1.6, 5.2.1). Furthermore,
grouping activity into quintiles seems too long a period for
everyday practice, although highly relevant from an epide-
miological perspective. The alternative is to define relapse as
infrequent (b1/yr), frequent (N2 relapses/y), or continuous
(persistent symptoms of active UC without a period of
remission)33 (Section 1.1.6).
6.1.3. Risk factors for relapse
Few prospective studies have assessed risk factors for relapse
in patients with inactive UC.196–200 In one study of 92
patients, a shorter duration of current remission and a higher
relapse frequency were predictive of further relapse.196 In a
second study of 64 patients, the frequency of previous re-
lapses, extraintestinal manifestations and a low-fibre diet
were independent variables associated with a higher risk of
relapse.197 In another study of 74 patients including various
biomarkers and clinical measures, a younger age, multiple
previous relapses (for women), and basal plasmacytosis on
rectal biopsy specimens were independent predictors of
relapse.198 This study did not confirm the two-fold increase in
relapse rate in those with persisting active inflammation
(polymorphonuclear leukocytes in the rectal mucosa) ob-
served in two earlier histopathology studies.201,202 The im-
pact of life events in relapse of UC has been examined
by a number of studies199,200,203 with contradictory results
(Section 11.3). Adherence to medical therapy appears to be
the governing factor associated with relapse, since the risk of
relapse was more than 5-fold higher (OR 5.5, 95%CI 2.3–13.0)
among 99 patients who collected b80% of their prescriptions
for maintenance mesalazine.204Patients with disease requiring steroids probably have
a different outcome to the overall population of patients
with UC. In a population-based study from Olmsted County,
Minnesota, the outcome of 183 patients with UC diagnosed
between 1970 and 1993 was analysed one year after a first
course of steroids.205 Among the 63/183 patients treated
with corticosteroids, 49% had a prolonged response, 22%
ECCO statement 6D
Oral 5-aminosalicylate (5-ASA) containing com-
pounds are the first line maintenance treatment
in patients responding to 5-ASA or steroids (oral or
rectal) [EL1a, RG A]. Maintenance with topical 5-
ASA is a valuable alternative in proctitis and left-
sided colitis [EL1b, RG A]. A combination of oral
and rectal 5-ASA can be used as a second line
maintenance treatment [EL1b, RG B]
40 S.P.L. Travis et al.were steroid dependent and 29% came to colectomy, but only
3/183 were treated with AZA/MP (see also Section 5.4.2).
6.2. Medications for maintenance of remission
Details of the action, dosage, side effects and monitoring of
aminosalicylates, steroids, thiopurines, and infliximab are in
the Active Disease section.
6.2.1. Aminosalicylates
6.2.1.1. Oral 5-ASA. The most recent version of the
Cochrane meta-analysis showed that the Peto odds ratio
for the failure to maintain clinical or endoscopic remission
(withdrawals and relapses) for oral 5-ASA vs placebo was 0.47
(95% CI, 0.36–0.62), with a number-needed-to-treat (NNT)
of 6.206 Randomised controlled trials (RCTs) designed to
evaluate the efficacy of oral 5-aminosalicylates (5-ASA) –
including sulfasalazine, mesalazine and olsalazine – for
maintaining remission are shown in Table 6.1.207–214
6.2.1.2. Rectal 5-ASA. Several RCTs have compared rec-
tal mesalazine in various formulations and regimensTable 6.1 Placebo-controlled trials of oral 5-aminosalicylates fo
Author [ref] Year Number of
patients
Study drug
Misiewicz207 1965 67 SZP
Placebo
Dissanayake208 1973 64 SZP
Placebo
Riis209 1973 59 SZP
Placebo
Sandberg-Gertzen210 1986 101 OLZ
Placebo
Wright211 1993 101 OLZ
Placebo
Miner212 1995 205 MSZ2
Placebo
Hanauer213 1996 264 MSZ3
MSZ
Placebo
Hawkey214 1997 323 MSZ3
Placebo
1pb0.05; 2Pentasa; 3Asacol/Claversal; 4pb0.05 for comparison of 5-AS
shown) and placebo; (sulfasalazine: SZP; olsalazine: OLZ, and mesalazwith placebo for maintenance of remission in distal UC
(Table 6.2).215,227–237 At 12months, failure tomaintain clinical
or endoscopic remission was 20–48% in the active arms
compared to 47–89% in the placebo arms. In all but one of
the trials, the differences in failure to maintain remission
between active and placebo groups were statistically sig-
nificant. The only RCT that failed to demonstrate efficacy of 5-
ASA suppositories215 followed a three times a week regimen;
the difference between the two arms was significant at 3, 6
and 9 months but did not reach the significance level at
12 months. Other trials have demonstrated efficacy with
similar intermittent rectal 5-ASA regimens, either alone or in
combination with oral 5-ASA. A meta-analysis which included
the two placebo-controlled trials, showed a superiority of
rectal mesalazine over placebo for remission maintenance at
1 year (OR 16.2, 95% CI 4.7–55.9).11
6.2.1.3. Combining oral and topical 5-ASA therapy. There
have been two RCTs comparing combination treatment with
oral mesalazine plus intermittent mesalazine enema to oral
mesalazine alone for maintaining remission (Table 6.2).
Remission rates were higher in patients receiving the combi-
nation. There are also three small RCTs comparing sulfasa-
lazine 2 g/day or oral mesalazine 1.6 g/day to intermittent
rectal mesalazine, with a trend in favour of the rectal
treatment (Table 6.2).
It is therefore clear that oral or rectal 5-ASA is superior to
placebo in maintaining remission in UC. The data suggest
that rectal 5-ASA has equivalent or slightly superior efficacy
to oral mesalazine in distal UC. The combination of oral
mesalazine and intermittent rectal 5-ASA appears to provide
further benefit. Although most authors in the studies claimed
that patients found long-term rectal treatment acceptable,
a postal survey of the UK patients showed that 80% pre-
ferred oral treatment alone.216 However, in another study
in Spain, 5-ASA suppositories were generally well toleratedr maintaining remission in UC
Dosage (g/day) Duration
(months)
Failure to
maintain clinical or
endoscopic remission
2 12 29%
76%1
2 6 22%
55%1
2 6 29%
24%
1 6 23%
45%1
2 12 63%
69%
4 12 43%
62%1
0.81.6 6 56%
56%
71%4
1.6 6 40%
59%1
A (both groups) vs placebo; 5comparison of 5-ASA, zileuton (not
ine: MSZ).
ECCO statement 6E
The minimal effective dose of oral 5-ASA is around
1 g per day [EL1a, RG A]. For rectal treatment 3 g/
week in divided doses is sufficient to maintain
remission. The dose can be tailored individually
according to efficacy and in some cases higher doses
±topical 5-ASA may be useful [EL5, RG D]. Although
sulfasalazine is equally or slightly more effective
[EL1a, RG A], other oral 5-ASA preparations are
preferred for toxicity reasons. All the different
available preparations of oral 5-ASA are effective
[EL1a, RG A]. At the moment, there is no robust
evidence to support the choice of any specific 5-ASA
preparation for maintenance [EL1a, RG A]
41ECCO Consensus on UC: Current managementand considered comfortable for treatment of at least one
year.217 The choice and options should be discussed with
patients. Adding rectal therapy is a treatment option for
patients who have relapsed on oral 5-ASA alone, although
adherence to prescribed therapy should be addressed.Table 6.2 Randomized controlled trials of rectal mesalazine com
in distal UC
Author [ref] Year Number of
patients
Study drugs Dosag
Sutherland227 1987 29 MSZ enema 2
MSZ enema 4
Biddle228 1988 25 MSZ enema 1
Placebo -
D'Arienzo229 1990 101 MSZ suppository 0.8
Placebo –
D'Albasio230 1990 79 MSZ enema 4 g×7
MSZ enema
Oral SZP 2g/da
Miner231 1994 92 MSZ enema 4 g/d
MSZ enema 4 g/2
MSZ enema 4 g/3
Placebo –
Andreoli232 1994 31 MSZ enema 4 gx2
Oral SZP 2g/da
Mantzaris233 1994 38 MSZ enema 4 g /3
Oral MLZ 1.5g/
D'Albasio234 1997 69 MSZ enema+oral 2×4 g
Oral MSZ alone 1.6g/
D'Albasio235 1998 111 MSZ suppository 0.5×2
MSZ suppository 0.5/d
Placebo –
Marteau215 1998 95 MSZ suppository 3×1 g
Placebo –
Hanauer236 2000 65 MSZ suppository 0.5
Placebo
Yokoyama237 2007 24 MSZ enema+oral 1 g×2
Oral MSZ alone 3g/da
1pb0.05; 2pb0.05 at months 3,6 and 9, but the difference did not reac
MSZ: mesalazine; SZP: sulfasalazine.6.2.1.4. Dose-response effect. A dose-response for main-
tenance of remission with mesalazine at doses greater
than 0.8 g/day has not been established (Tables 6.1–6.3).
In an Italian study, no difference was found in relapse rates at
1 year on mesalazine 1.2 g compared to 2.4 g/day.218
Patients taking the higher dose were in remission for longer
than those on the lower dose (median time in remission of
175 days vs 129 days, pb0.001), but it may be debated
whether this is clinically significant. For those with extensive
UC, however, the benefit of the higher dose was more
marked (143 days vs 47 days, pb0.005). When the results for
patients in remission at 12 months were analysed after
stratifying for frequently relapsing (N3 relapses per year)
vs less frequent relapses, 2.4 g/day was also performed
significantly better than 1.2 g/day (75% vs 33%, respec-
tively). This post hoc analysis must, however, be treated
with caution.219 Another trial has also reported a trend for
benefit in subjects receiving the higher dose of Pentasa 3 g/
day compared with 1.5 g/day (p=0.051).220 As with other
studies of high doses of 5-ASA, there was no increase in the
frequency of adverse events. It is possible that high doses of
maintenance oral mesalazine are required in some patients,
perhaps in those that required high doses of oral 5-ASA to
induce remission or those with frequently relapsing disease,pared to placebo or oral formulations for maintaining remission
e (g/day) Duration
(months)
Failure to maintain clinical
or endoscopic remission
6 40%
46%
12 25%
85%1
12 20%
80%1
/month 4 g/3days 24 31%
28%
y 39%
ay 6 19%
days 28%
days 35%
52%1
/week 12 25%
y 40%
day 24 26%
day 68%1
/week+1.6 g/day 12 39%
day 64%1
/day 12 10%
ay 32%
47%1
/week 12 48%
62%2
24 46%
89%1
/week+3 g/day – 18%
y 77%
h the significance level at month 12.
42 S.P.L. Travis et al.but at present, there is no good evidence to support this.221
There are also no data supporting a dose-response relation-
ship with rectal 5-ASA for maintaining remission in distal UC
(Table 6.2), and no more than 1 g/day is necessary for rectal
5-ASA therapy.
6.2.1.5. Comparison of oral 5-ASA formulations. In the
Cochrane meta-analysis206 the odds ratio for the failure to
maintain clinical or endoscopic remission (withdrawals and
relapses) was calculated for the trials in which sulfasalazine
and 5-ASA were compared (Table 6.3).238–250 The odds ratio
was 1.29 (95%CI 1.05–1.57), with a negative NNT, suggesting
greater therapeutic effectiveness for sulfasalazine. Sulfasa-
lazine and 5-ASA had similar adverse event profiles (OR 1.16,
95% CI 0.62–2.16, and OR 1.31, 95% CI 0.86–1.99 respec-
tively). However, the trials that compared 5-ASA and sul-
fasalazine are likely to have been biased in favour ofTable 6.3 Trials comparing different oral 5-aminosalicylate form
Author [ref] Year Number of
patients
Study drugs
Azad Khan238 1980 170 SZP
SZP
SZP
Andreoli239 1987 13 MSZ
SZP
Ireland240 1988 164 OLZ SZP
Riley241 1988 92 MSZSZP
Mulder242 1988 72 MSZSZP
McIntyre243 1988 79 BLZ
SZP
Rutgeerts244 1989 273 MSZ1SZP
Kiilerich245 1992 226 OLZ
SZP
Rijk246 1992 46 OLZ
SZP
Courtney222 1992 99 OLZ
MSZ1
Travis247 1994 198 OLZ
OLZ
OLZ
Ardizzone248 1995 88 MSZ1
SZP
Kruis249 1995 160 OLZ
OLZ
OLZ
SZP
Nilsson250 1995 OLZ
SLZ
Fockens220 1995 169 MSZ
MSZ4
Paoluzi218 2005 156 MSZ1
MSZ1
1Asacol/Claversal; 2pb0.05; 3failure including relapses plus study w
frequent in the 3 g group.sulfasalazine, because most trials enrolled sulfasalazine-
tolerant patients, which would have minimized sulfasala-
zine-related adverse events. There is only one, single-blind
RCT218,220,222 comparing olsalazine 1 g/day head to head
with oral mesalazine 1.2 g/day as maintenance for UC. At
1 year, remission rates were 75% and 54%, respectively
(p=0.02). The frequency of adverse events was low in this
study, especially the rate of diarrhoea in the olsalazine
group, perhaps because there was a predominance of pa-
tients with distal UC. This study has not been replicated and
the dose inequivalence noted, although this is unlikely
to have mattered (above). No controlled trial has yet
been published on maintenance of remission with mesalazine
MMx.
6.2.1.6. Adherence to 5-ASA treatment. Adherence to 5-
ASA appears to be important for improving outcome ofulations and dosages for maintaining remission in UC
Dosage (g/day) Duration
(months)
Failure to
maintain clinical or
endoscopic remission
1 6 33%
2 14%
4 9%2,6
0.75 12 43%
1.5 17%
1 6 43%
2 26%2
0.82 12 40%
46%
1.5 12 45%
3 56%
2 6 49%
2 37%
0.75–1.5 12 54%
2 42%
1 12 54%
2 49%
1.5–2 12 46%
3–4 48%
1 12 25%
1.2 46%2
0.51 12 52%
2 40%
40%3
1 12 38%
2 51%
0.51.25 6 36%
2 49%
2 24%
32%
1.5 12 46%
3 33%5
1.2 12 74%
2.4 70%
ithdrawals; 4Pentasa; 5p=0.057; unacceptable side-effects were
43ECCO Consensus on UC: Current managementpatients with UC. When the adherence rate in 94 outpatients
on 5-ASA with clinically quiescent UC for at least 6 months
was studied, the overall adherence rate was 40% and the
median amount of medication dispensed per patient was 71%
(8–130%) of the prescribed regimen.223 Logistic regression
identified a history of four or more prescriptions and male
gender increased the risk of non-adherence. Being married,
having extensive disease or having an endoscopy within the
past 24 months reduced non-adherence. The same group
conducted a prospective study to determine the effects of
non-adherence with 5-ASA among 99 patients with quiescent
UC. After 12 months, patients who collected b80% of their
prescriptions had a 5-fold higher OR (5.5, 95% CI 2.3–
13.0).204 In a pilot study, patients were randomized to
receive either once-daily or conventional (twice or three
times daily), mesalazine for maintenance of remission in
UC.224 After 6 months, patients in the once-daily arm
appeared more satisfied with their regimen and consumed
more medication than those in the conventional arm (90%
vs 76%; p=0.07). The authors concluded that once-daily
oral formulations of 5-ASA were likely to be a better
therapeutic option due to their ability to offer compar-
able efficacy and improved adherence. This premise
appears correct. An investigator-blinded study of 362
patients randomised to receive Pentasa 2 g once daily or
1 g twice daily, showed a 12% better remission rate at
1 year (73.8% vs 63.6% respectively) in the single daily
dose group.225 Patient questionnaires showed significantly
greater compliance (pb0.05) and acceptability (pb0.001)
in the once daily group. The study has yet to be reported
in full, but given comparable efficacy between once daily
and divided dosing regimes for the treatment of active UC
with mesalazine MMx (Mezavant®/Lialda®) and Salo-
falk®,23-25,226 the effect is likely to be generic rather
than compound-specific.
6.2.2. ThiopurinesECCO statement 6F
Azathioprine/mercaptopurine is recommended
for patients who have experienced early or
frequent relapse while taking 5-ASA at optimal
dose or who are intolerant to 5-ASA [EL5, RG D],
patients that are steroid-dependent [EL1a, RG A]
and for patients responding to ciclosporin (or
tacrolimus) for induction of remission [EL3, RG C].
Azathioprine/6-MP can also be considered in a
patient responding to intensive treatment with
intravenous steroids for induction of remission
[EL5, RG D]. Addition or continuation of oral 5-
ASA can be recommended with special attention
to potential myelotoxicity [EL5, RG D]6.2.2.1. Efficacy of thiopurines for maintenance of
remission. Seven RCTs evaluating the efficacy of thiopurines
azathioprine (AZA) and mercaptopurine (MP) for maintenance
of remission in UC are listed in Table 6.4.136,175,182,251–254 In
the Cochrane meta-analysis published after the Consensus
meeting,255 six of these studies on 286 patients wereconsidered. The study quality was judged generally
poor and the evidence for using thiopurines in UC is weaker
than that forCrohn's disease.158AZAwas showntobe superior to
placebo on the basis of four trials (OR for failure to maintain
remission 0.41, 95% CI 0.24–0.70). The results were similar
when analyses were limited to patients who had successful
induction of remission (data available for two studies). There
was no clear evidence of a dose-response effect for AZA, or for
use of co-medicationwithmesalazine in these studies. The two
open label studies that compared MP to mesalazine and AZA to
sulfasalazineshowedsignificantheterogeneityandcouldnotbe
pooled. Adverse effects occurred in 11/127 patients receiving
AZA, including acute pancreatitis (3 cases) and bone marrow
suppression (5 cases). Since this meta-analysis, a further RCT
hasbeenpublishedbyArdizzoneetal.136 72patientswithactive
steroid-dependent UC were randomised (investigator-blind) to
AZA 2 mg/kg/day or mesalazine 3.2 g/day for 6-months.
Steroid-free, clinical and endoscopic remission was achieved
in 53% on AZA, compared to 21% given 5-ASA (intention to treat
analysis: OR 4.78, 95% CI 1.57–14.5). This is the best trial to
date.
Evidence in support of the thiopurines for UC also comes
from observational cohorts in retrospective series.256–262
The best among these is the 30 year cohort from the Oxford
IBD clinic between 1968 and 1999.262 In this series, the
overall remission rate in the 346 patients with UC who were
treated with AZA was 58%, but increased to 87% among
patients on therapy for more than 6 months. The proportion
of patients in remission at 5 years was 62% applying a strict
definition of relapse, or 81% allowing for a brief relapse with
a short corticosteroid course. The median time to relapse
after stopping AZA was 18 months.
6.2.2.2. Thiopurines after ciclosporin (or tacrolimus) for
induction of remission. Calcineurin inhibitors are rescue
therapy options for steroid-refractory UC (see Section 5.2.5).
Since calcineurin inhibitors are best discontinued within
6 months because of nephrotoxicity, these agents are
generally proposed as induction therapy until slower-acting
immunomodulators such as AZA or MP become effective. AZA
or MP are introduced while the patient is still on ciclosporin
(CsA) or tacrolimus and steroids are being tapered. The
justification of thiopurines in this setting, even in patients
who are 5-ASA naive, is the high colectomy rate (36-69% in
the 12 months following introduction of CsA, Section 5.2.5
63–65). Restrospective series have suggested that thiopurines
reduce the risk of colectomy after the induction period
with CsA.63,263–265 In 1996, a series of 29 patients success-
fully treated with ciclosporin were followed for a median
92 weeks, and 22% of patients taking MP required a
colectomy, compared to 72% of those not taking MP.263 In
another series 5/19 patients receiving AZA (26%) underwent
colectomy during the follow-up, compared to 9/11 subjects
(81%) who did not receive AZA maintenance (p=0.01).265
Similar results have been reported from Chicago: of 36/42
initial responders to CsA, 25 (69%) also received MP or AZA, of
whom 20% required colectomy vs 45% who did not thiopurines
during the 5 year follow up.63
After intravenous CsA, a switch to oral therapy occurs
as soon as a clinical response has been achieved, with a
view to acting as a ‘bridge’ until the therapeutic effect of
AZA is achieved. Nevertheless, the usefulness of the oral
ECCO statement 6G
In a patient responding to infliximab, infliximab is
recommended for maintenance treatment [EL1b,
RG A]. In azathioprine naïve patients responding to
infliximab induction, azathioprine is an option
instead of infliximab for maintenance [EL5, RG D]
Table 6.4 Randomized trials of thiopurines compared to placebo or oral 5-aminosalicylates for maintaining remission in UC
Author [ref] Year Number
of patients
Study drugs Dosage Study design Duration
(months)
Failure to
maintain clinical or
endoscopic remission
Jewell175 1974 80 Azathioprine 2.5 mg/kg/day
then reduced to
1.5–2 mg/kg/day
after 3 months
Double-blind 121 60%
Placebo – 77%
Hawthorne251 1992 672 Azathioprine 100 mg/day Double-blind 12 36%
Placebo – 59%3
Mate-Jimenez182 2000 34 6–mercaptopurine 1 .5 mg/kg/day Open label 181 50%
Methotrexate 15 mg/week 85%
MSZ 3g/day 93%3
Sood252 2000 50 Azathioprine4 2.mg/kg/day Single (patient)-
blind
121 44%
Placebo – 60%3
Sood253 2002 35 Azathioprine4 2.5 mg/kg/day Double-blind 121 23%
Placebo – 56%
Sood254 2003 25 Azathioprine+
SZP
2 .5 mg/kg/day+
6 g/day
Open label 181 77%
SZP 6g/day 44%3
Ardizzone136 2006 72 Azathioprine 2 m g/kg/day Single 6 47%
MSZ 3.2g/day (Investigator)-
blind
79%3
1Inclusion of patients with active disease who initially received steroids for induction of remission.
2All patients included in this study were in remission on azathioprine for at least 6 months (withdrawal design); co-medication with 5-ASA
was permitted and taken by 82% of patients.
3pb0.05.
4Co-medication with sulfasalazine 6 g/day in all patients.
44 S.P.L. Travis et al.CsA bridge has been challenged. In a retrospective series
from Barcelona, all responders to iv CsA were treated with
AZA, without oral ciclosporin.266 Cumulative probabilities
of relapse were 42%, 72% and 77% at 1, 3 and 5 years, and
cumulative probabilities of colectomy were respectively
29%, 35% and 42%. These are similar to or better than
those reported in the literature, so the authors concluded
that the ‘bridging step’ with oral CsA may not be
necessary. This needs more investigation.
Three retrospective studies have assessed the long term
outcome of patients after an attack of UC treated with
intravenous CsA.63–65 All describe a high rate of relapse and
colectomy. In 76 patients treated with CsA for intravenous
steroid-refractory UC, 65% relapsed within 1 year, and 90%
within 3 years 90%.64 Unusually, a beneficial effect of AZA
(given to 35/56 who could tolerate it) could not be
demonstrated either to maintain remission or prevent
colectomy (ns). After 5 years 47% in the non-AZA and 40%
in the AZA-treated patients came to colectomy, and after
7 years the overall colectomy rate was 58%. The Leuven
experience described 142 patients, 118 (83%) of whom had
an initial response to CsA and avoided colectomy during
initial hospitalization.65 64/118 (54%) subsequently
required colectomy. The rate of colectomy in those already
on AZA compared with those starting AZA concurrently with
CsA was 59% vs 31%, respectively (pb0.05). Life-table
analysis showed that 33% of patients required colectomy
at 1 year, but the probability increased to 88% at 7 years if
CsA was used in patients already on AZA. Consequently CsAhas little role for patients who have failed AZA of an
appropriate dose and duration.
6.2.3. Infliximab (IFX)6.2.3.1. Efficacy for maintenance. Details of the ACT 1 & 2
studies are given in Section 5.4.3.78. The design of these studies
was different to standard maintenance trials (Section 6.1.1).
Patients included in the maintenance phase were not necessa-
rily in steroid-free clinical or endoscopic remission. Moreover,
non-responders to IFX were taken into account in the
calculation of week 30 and week 54 response or remission
rates. In both studies, a significantly higher proportion of
patients had a clinical response or remission on IFX at weeks 8
and30 (andatweek 54 in theACT1 trial), compared to placebo.
In ACT 1, remission rates at week 54 were 35% (5 mg/kg), 34%
(10mg/kg) and 17% (placebo). In ACT 2, remission rates atweek
30 were 26% (5 mg/kg), 36% (10 mg/kg) and 11% (placebo). The
proportion of patients with a sustained clinical remission at all
time points was 7% (placebo) and 20% (5 mg/kg) after 54 weeks
45ECCO Consensus on UC: Current managementin ACT 1, and 2% (placebo) and 15% (5 mg/kg) after 30 weeks in
ACT 2. The steroid-free remission rates in the 74 patients
receiving corticosteroids at baselinewereverymodest although
still statistically significant. In ACT 1, steroid-free remission at
week 54was achieved in 24% (5mg/kg), 19% (10mg/kg) and 10%
(placebo). In ACT 2, the corresponding values at week 30
(7months) were 18%, 27% and 3%. The rates of clinical response
and remission were similar between the subpopulations of
patients who were “corticosteroid-refractory” (i.e., those
receiving corticosteroids at baseline) and those who were
“not corticosteroid-refractory”.
6.2.3.2. Combining IFX and immunomodulators.ECCO statement 6I
E. coli Nissle is an effective alternative to 5-ASA
for maintenance [EL1b, RG A]
ECCO statement 6H
Combination of infliximab with an immunosup-
pressant for at least 6 months, or premedication
with steroids, is currently recommended in order
to decrease immunogenicity [EL3, RG C]As with Crohn's disease,158 the combination of IFX and a
thiopurine analogue or corticosteroids is probably justified to
decrease immunogenicity, which is the source of infusion
reactions and loss of response.267,268 Since antibodies to IFX
occur early in the treatment, the question of discontinuing the
immunomodulator has been addressed by the Leuven group for
Crohn's disease. Results from a single centre open-label
randomized, withdrawal trial suggest that the immunomodu-
lator can be stopped after 6 months with no loss of response to
IFX over 2 years.269 These results should still be interpretedwith
caution, because circulating concentrations of IFX declined over
time when the immunomodulator was discontinued. On the
other hand, the report of eight cases of a rare form of
hepatosplenic T cell lymphoma occurring in young patients
treated concurrently with IFX and thiopurines must also be
taken into account.270 Short-term combination (6 months)
appears to offer a good balance between risks and efficacy for
those in whom IFX is continued. If a patient is naïve to AZAwhen
given IFX, a reasonable option is todeterminewhether remissionTable 6.5 Randomized trials of probiotics for maintaining remis
Author [ref] Year Number of patients Study drugs
Kruis274 1997 120 E. coli Nissle
Mesalazine
Rembacken275 1999 116 E. coli Nissle
Mesalazine
Kruis276 2004 327 E. coli Nissle
Mesalazine
Ishikawa277 2000 21 Probiotic mixture1num
Treatment2
Zocco278 2006 187 Lactobacillus GG
Mesalazine
Combination
1Bifidobacterium bifidum+Bifidobacterium breve+Lactobacillus acido
2Open label study.will be maintained by AZA alone, without committing that
patient to maintenance IFX.
Whether IFX acts as a bridge to remission that ismaintained by
thiopurines, or whether AZA simply slows the rate of descent to
inevitable relapse (the ‘parachute’271), remains debated. This
strategyhasnotyetbeen tested inUC,but is anacceptableoption
for thiopurine-naive patients with steroid-dependent Crohn's
disease.272 The 2 year follow up of patients who received a single
dose of IFX as rescue therapy for intravenous steroid-refractory
UC (Section 5.2.573) presented after the Consensus meeting,
showed that 13/16 patientswho receivedAZA avoided colectomy
(with orwithout oral 5-ASA) compared to 5/8who received 5-ASA
alone (ns).273 Consequently, whether maintenance IFX (with or
without thiopurines) is better than thiopurines alone to prevent
relapse and avoid late colectomy cannot be deduced.
6.2.4. ProbioticsE. coli strain Nissle 1917.
Three RCTs have compared the E. coli strain Nissle 1917
(Mutaflor®) to mesalazine for maintenance of remission in UC
(Table 6.5). In the first study, 120 outpatients in a multicentre,
double-blind, study received 1.5 g/day 5-ASA or 100 mg/day E.
coli strain Nissle (corresponding to 25×109 viable E. coli
bacteria) for 4 days, and then 200 mg/day.274 No concomitant
medications were permitted. After 12 weeks, 11% of patients
receiving 5-ASA and 16% of those receiving the probiotic
patients relapsed. The statistical power was limited by the
short duration of the study, because relatively few patients
relapsed, but an 11–16% relapse rate within 3 months seems
rather high. Subsequently 116 patients with active UC were
randomized to receive either 5-ASA 2.4 g/day, reducing to
1.2 g/day after remission, or 200 mg/day of E. coli strain
Nissle.275 All patients also received an initial 7 day course of oral
gentamicin and either rectal or oral steroids in variable doses.sion in UC
Dosage Duration (months) Failure to maintain
clinical or endoscopic
remission
200 mg/day 4 16%
1.2g/day 12%
200 mg/day 12 73%
1.2g/day 73%
200 mg/day 12 45%
1.5g/day 36%
ber 100 mL 12 27%
90%3
18×109 12 15%
2.4 g/day 20%
16%
philus.
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group, and 68% in the corticosteroid plus E. coli group (ns).
During the one year follow up, relapse occurred in 73% of the 5-
ASA group and 67% of the E. coli group (ns) after weaning off
steroids. This is a very high relapse rate for reasons that are
unclear, but the probiotic was no less effective than 5-ASA.
Finally, an equivalence study was conducted.275 327 patients
with UC in remission for no longer than 12months were treated
with either 5-ASA 1.5 g/day or E. coli Nissle 1917 for 1 year. The
relapse rate was 45% in the E. coli group vs 36% in the
mesalamine group. The corresponding one-sided upper 95%
confidence interval for the difference in treatment was
12.8%, which is within the equivalence range of 20% required
for acceptance of the non-inferiority hypothesis. It was
concluded that E. coli strain Nissle 1917 is not inferior to the
established standard 5-ASA for maintenance of remission in
UC, although the relapse rate in this last study was still
higher than expected.206
6.2.4.1. Other probiotics. No other probiotic has been sub-
ject to properly powered RCTs. When 100 ml/day of fermented
milk containing Bifidobacterium bifidum YIT 4007, B. breve YIT
4065, and L. acidophilus YIT 0168 was given to 21 UC patients
over 1 year,277 neither investigators nor patients were blinded,
and other treatments could be administered. There were fewer
relapses in the treatment arm (27% in the milk group vs 90% in
the controls), but nodifferences inendoscopic lesions.Another
group of 187 patients with UC in remission for less than
12monthswere randomised to receive either LactobacillusGG
18×109 viable bacteria/day, 5-ASA 2.4 g/day, or the combina-
tion.278 There were no differences in sustained clinical or
endoscopic remission rates at 6 and 12 months between the
three treatment groups. In a post-hoc analysis, however,
treatment with Lactobacillus GG appeared to prolong the
relapse-free time compared to 5-ASA. Relapse rates at
12 months were 136/10,000 person-months on Lactobacillus
GG alone and 181/10 000 person-months on 5-ASA (p=0.01).
Further studies are needed.
6.2.5. Other treatments
6.2.5.1. Antibiotics. The potential benefit of adding cip-
rofloxacin to conventional therapy has been investigated.279 In
a randomized, placebo-controlled, double-blind clinical trial,
ciprofloxacin (1–1.5 g/day) or placebo was administered for
6 months to 83 patients referred with active UC refractory to
conventional treatment. All the patients were initially treated
with a high but decreasing dose of prednisone and with 5-ASA.
Treatment failure was the primary end point, defined as both
symptomatic and endoscopic failure to respond. The treatment
failure rate was 21% in the ciprofloxacin-treated group and 44%
in the placebo group (p=0.02). The study design was more
appropriate for an induction rather than a maintenance study
and inclusion criteria, definition of clinical response and
concomitant therapies have been criticized.280 Consequently
ciprofloxacin should not be considered effective for maintain-
ing remission in UC. In another double-blind, randomized trial,
metronidazole (0.6 g/day) and sulfasalazine (2 g/day) were
compared for maintenance of remission in 40 patients with UC
in remission for less than 12 months.281 After 1 year,
metronidazole was found to be slightly more effective than
sulfasalazine. No significant side effects were noted, and inparticular, no paraesthesiae were reported. These data
are regarded as insufficient by the Consensus to recommend
antibiotics for maintenance of remission in UC.
6.2.5.2. Methotrexate. Data on methotrexate (MTX) for
maintenance of remission in UC are few. The single RCTwas
principally designed for induction of remission in refractory,
active UC and used a dose (12.5 mg/week) that is probably
sub-therapeutic (see Section 5.4.6).181 The proportions of
patients who relapsed after first remission (MTX 64% vs
placebo, 44%) were not significantly different. An open-label
study compared MP, MTX and 5-ASA in 72 steroid-dependent
IBD patients, including 34 with UC182 (Table 6.4). Patients on
prednisone were randomly assigned in a 2:2:1 ratio to
receive oral MP 1 mg/kg, MTX 15 mg/week, or 5-ASA 3 g/day.
All patients who achieved remission at week 30 were then
included in a maintenance study for 76 weeks. A significantly
higher proportion of patients achieved remission in the MP
group (79%) than in the 5-ASA group (25%), with no statistical
differences compared to the MTX group (58%). For main-
tenance of remission, the higher rate was found in the MP
group (64%) compared to MTX (14%) and 5-ASA (0%). Too many
questions were being addressed by this study for conclusions
on the relative efficacy of MP and MTX in UC to be drawn.
Several retrospective series have also been publish-
ed,183,282–285 to a total of 91 patients. Most had failed or
been intolerant of AZA and were treated with MTX at various
doses and routes of administration. The response or remission
rates ranged from 40% to 75%, suggesting that some patients
with UC may respond well to methotrexate. One study
distinguished between patients given MTX for AZA-intolerance
and AZA-failure.285 MTX (median oral dose 20 mg/week) was
tolerated by 27/31 (87%) patients who had been unable to
tolerate AZA. Of those treatedwithMTX after failurewithAZA,
5/11 patients had a colectomy vs 5/31 patients who were
intolerant of AZA (pb0.05). The results are heterogeneous and
it is possible that the dose of MTX is an important determinant
of efficacy, but the Consensus considered that there is
currently insufficient evidence to recommend MTX for UC.
6.2.5.3. Omega-3 fatty acids (fish oil). Preparations
containing omega-3 fatty acids and eicosapentaenoïc acid in
particular,may have anti-inflammatory properties by reducing
the production of leucotriene B4286,287 Several studies have
been conducted in UC with different formulations and dosing
of n-3 fatty acids.288–296 Only three randomized controlled
trials were selected for a Cochrane meta-analysis published
after the Consensus,297 which included 138 UC patients who
were in remission at the time of recruitment.291,293,294 The
pooled analysis showeda similar relapse rate in the n-3 treated
patients and controls (RR 1.02, 95%CI 0.51–2.03, p=0.96). No
significant adverse events were recorded.
6.2.5.4. Appendicectomy. Studies have focused on the role
of appendicectomy in the UC pathogenesis. A meta-analysis
included 13 case-control studies and suggested that appendi-
cectomy gives a 69% reduction in the risk of developing UC (OR
0.31, 95%CI 0.25–0.38;pb0.0001).298 The influence of potential
confounders such as smoking was excluded. The protective
effect of appendicectomy for the development of UC appears to
be limited to patients who undergo appendicectomy before age
20 years and is mainly observed for primary appendicectomy
ECCO statement 6 K
Due to lack of evidence, no recommendation can
be given for the duration of treatment with
azathioprine or infliximab, although prolonged
use of these medications may be considered if
needed [EL4, RG D]
47ECCO Consensus on UC: Current management(surgery for appendicitis) andnot for incidental appendicectomy
(removal of the appendix for other reasons).299 The outcome of
41 UC patients with an appendicectomy before diagnosis and
466 with no previous surgery, who were all prospectively in-
cluded in an IBD database, has been compared.300 Previous
appendicectomy has a beneficial effect on the course of UC,
witha lessmarkedyear-by-year disease activity andadecreased
risk of colectomy. This protective effect was additive to that of
current smoking. Similar results have been reported from the
Brisbane group, who have explored the subject in detail and
shown an association between previous appendicetomy for ap-
pendicitis andamild course of extensive colitis, but no influence
on the pattern of primary sclerosing cholangitis.301,302 There are
only anecdotal data on the course of UC when appendicectomy
is performed after UC diagnosis.103 Consequently, the Consensus
considered that there is no enough evidence to recommend
appendicectomy for preventing relapse in UC.
6.2.5.5. Biological and other therapy. Adalimumab, cer-
tolizumab, etanercept, natalizumab, visulizumab, inter-
leukin 10, fontolizumab (an anti-interferon γ antibody),
basiliximab, daclizumab, alicaforsen (an anti-ICAM1 anti-
sense molecule), anti-IL12 and anti-IL6 antibodies have not
yet been evaluated for maintenance of remission in UC, and
nor have leucocytapheresis, tacrolimus, or cyclophospha-
mide in any meaningful way.
6.3. Duration of maintenance therapyECCO statement 6J
The general recommendation is to continue 5-ASA
maintenance treatment long-term [EL3b, RG C]
since this may reduce the risk of colon cancer
[EL4, RG D]
ECCO statement 7A
A staged procedure (colectomy first) is recom-
mended in the acute case when patients do not
respond to medical therapy [EL 4, RG C], or if a
patient has been taking 20 mg or more of
prednisolone for more than 6 weeks [EL 4, RG C]In 1973, two studies from Sweden and the UK were
published to assess whether sulfasalzine was still effective at
preventing relapse in UC patients with a long duration of
remission (Table 6.1). In the Swedish study, the authors found
no statistical benefit to maintaining sulfasalazine for
patients who had been symptom-free on sulfasalazine for
more than a year.209 However, the number of patients was
small, the duration of follow-up only 6 months and patients
were selected on clinical symptoms without endoscopic or
histologic criteria. In the UK study, sigmoidoscopy and rectal
biopsy were used at entry.208 The authors found that
maintenance treatment with sulfasalazine 2 g/day continued
to have a major effect at reducing relapse, even in the
subgroup of patients who had been on sulfasalazine for more
than 3 years. Twenty-six years later, an Italian double-blind
withdrawal RCT included 112 patients with UC in clinical,
endoscopic and histological remission who had been on
sulfasalazine or 5-ASA for at least 1 year.303 Patients were
randomized to oral Asacol® 1.2 g/day or placebo for 1 year.
Despite the small numbers, patients were stratified accord-
ing to the length of disease remission prior to randomization.
In patients with disease remission for 1–2 years, mesalazine
appeared significantly more effective than placebo for
preventing relapse at 12 months (Asacol® 23% and placebo
49%, p=0.035). For patients who had been in remission formore than 2 years however, no statistically significant
difference was observed between relapse rates (5/28 vs 6/
23, or 18% vs 26%, respectively), but numbers were very
small. The results of this study should be regarded with
caution, not only because of the low power, but also because
the trend was in favour of continuing mesalazine. The debate
about the merits of 5-ASA for chemoprevention of colorectal
cancer is covered in Section 9.5.7. Surgery
7.1. General
Surgery for ulcerative colitis has been refined to offer patients
needing colectomy a better quality of life. Until the early
1980 s, the gold standard for surgery was proctocolectomy
with an ileostomy, apart from the sporadic use of ileorectal
anastomosis. The Kock continent ileostomy was introduced in
the late 1960 s, but never achieved universal acceptance,
although the gain in quality of life compared to proctocolect-
omywith a conventional stoma seemed clear enough.304 In the
past 20 years, the new gold standard has become the
restorative proctocolectomy with ileal pouch-anal anastomo-
sis (IPAA), offering patients an unchanged body image with no
stoma and a preserved anal route of defaecation.305 Never-
theless, bowel function is not restored to normal and both
functional outcomeandquality of life after IPAA have still to be
compared to living with an ileostomy.306
This section deals with some aspects on surgery for
ulcerative colitis. IPAA is probably one of the most frequently
described procedures in colorectal surgery. There have been
a vast number of publications (498 papers, 58 reviews), but
despite this good quality evidence in terms of randomised
studies are scarce (5 on different aspects of pouch surgery),
as is so often the case in surgery. The indications and timing
of surgery for UC are found in the appropriate sections (acute
severe colitis, Section 5.2.4; refractory colitis, Section
5.2.5; dysplasia or cancer, Section 9.4.2).
7.2. Technical considerations
7.2.1. Surgery for acute severe colitis
ECCO statement 7C
When performing pouch surgery, the maximum
length of anorectal mucosa between the dentate
line and the anastomosis should not exceed 2 cm [EL
4, RG C]
48 S.P.L. Travis et al.A staged proctocolectomy (subtotal colectomy first) is
considered by many surgeons to be a wise first step in the
surgical treatment of ulcerative colitis in acute severe
colitis or if patients are saturated with steroids. This is
probably even wiser today when medical therapy for
acute severe colitis is prolonged for more than 5 days. A
subtotal colectomy with an ileostomy will cure the patient
from the burden of the colitis, allowing them to regain
general health, normalise nutrition and give the patient
time to consider carefully the option of an IPAA or,
perhaps, permanent ileostomy. A preliminary subtotal
colectomy also allows the pathology to be clarified and
Crohn's to be excluded. Subtotal colectomy is a relatively
safe procedure even in the critical ill patient.307–309
However it is seldom considered the final solution. Thus
patients have to go through additional surgery which
incurs further risks, additional costs and a prolonged time
under surgical care.
7.2.2. Managing the rectal remnantECCO statement 7E
When the indication for surgery is cancer or
dysplasia and restorative proctocolectomy is
performed, anastomosis at the dentate line is
recommended [EL4, RG C]
ECCO statement 7B
When performing a colectomy for ulcerative
colitis in emergency circumstances, the whole
rectum should be preserved [EL 4, RG C]. Whether
to preserve additional recto-sigmoid colon and
how to deal with bowel closure is left to the
surgeon´s decision [EL 4, RG C]
ECCO statement 7D
When performing an IPAA it is mandatory that the
surgical team can also perform a mucosectomy and
a hand-sewn anastomosis should the stapled
anastomosis fail [EL5, RG D]There are some technical aspects on how to deal with
the rectum when performing an emergency subtotal
colectomy. These might have a bearing on the complica-
tion rate and have technical implications when the patient
comes to a later proctectomy. Leaving as little rectum as
possible (i.e., dividing the middle rectum within the
pelvis) is not to be recommended, as this will render
subsequent proctectomy difficult, with a probable
increase in the risk of pelvic nerve injury. The alternatives
are to divide the rectum at the level of the promontory
(i.e., at the proper rectosigmoid junction) or to leave in
addition the distal part of the sigmoid colon. This allows
the bowel to be either anchored to the anterior abdominal
wall, facilitating subsequent identification and dissection,
or to bring the bowel up through the abdominal fascia
either closed in the subcutaneous fat, or brought forward
as a mucous fistula. The latter option is considered very safe,
because no closed bowel is left within the abdomen, but the
mucous fistula gives the patient another stoma that is not so
easily managed.310 Closing the stump and leaving it within the
subcutaneous fat is as safe, although the skin is probably best be
left to heal through secondary intention in order to avoid wound
infections.311 There are no studies that give information on the
risk of subsequent inflammation or bleeding after leaving
differing lengths of rectum or rectosigmoid colon. When the
rectum is transsectedwithin the abdominal cavity at the level of
the promontory, then this warrants transanal rectal drainage for
some days, to prevent blow out of the rectal stump due to
retention.7.2.3. Site of anastomosis for restorative poctocolectomyThe now commonly used stapling technique for performing
the ileo-anal anastomosis usually leaves a remnant of
anorectal mucosa above the dentate line. This can be a
cause of persistent inflammation (‘cuffitis’), with pouch
dysfunction and a risk of dysplasia or (very rarely) cancer.312
On the otherhand, a very short lengthofmucosa (b1 cm) above
the dentate line would exclude many (or even most) male
patients from the stapling technique, due to technical
problems achieving a low anastomosis in the narrow male
pelvis. Both have to be balanced against the advantage of the
stapling technique, which gives patients better nocturnal
continence.313
7.2.4. Anastomostic technique for restorative
proctocolectomyNevertheless, the stapling technique occasionally fails, is
impossible, or inappropriate. There is then seldom room for
re-stapling and the only way of avoiding a permanent stoma
is to hand-sew the anastomosis. Stapling is generally
inappropriate when performing IPAA for dysplasia or cancer
complicating colitis, since the Consensus is to remove all
mucosa (Statement 7E, below). All these eventualities mean
being able to hand-sew the anastomosis.
7.2.5. Site of anastomosis for neoplasia complicating colitisSince the stapling technique commonly leaves epithelium
which may still have malignant potential, the alternative is
to perform a mucosectomy from the dentate line. In theory,
but not necessarily in practice, this removes all of the
potentially diseased (and pre-malignant) mucosa. Conse-
quently if the indication for proctocolectomy is cancer
complicating colitis, this might influence the subsequent
risk of cancer.314 However, the literature reports cancers
both in patients with a stapled anastomosis as well as in
49ECCO Consensus on UC: Current managementthose who have had a mucosectomy, but almost exclusively
in those who had pre-existing malignancy in the resected
colon. The number of reported cancers is limited (b30 out of
tens of thousands of IPAA performedworld wide) and is not at
present a matter for alarm.315,316 When there is colonic
dysplasia alone rather than cancer, the literature gives no
advice on whether to staple or perform a mucosectomy. A
total mesorectal excision is, however, mandatory when the
indication is dysplasia or cancer.
7.2.6. Role of covering ileostomy for restorative
proctocolectomyECCO statement 7F
When performing a restorative proctocolectomy
for ulcerative colitis a covering loop ileostomy is
generally recommended, but it can be avoided in
selected cases [EL 3b, RG C]
ECCO statement 7I
Follow up should be individualised and focus on
those patients with signs of chronic inflammation
in their mucosa [EL 5, RG D]One of the main complications of IPAA surgery, and also the
complication that might jeopardise the final outcome of the
operation, is a leak in the suture lines of the anastomosis or
pouch. Whether the consequences of a leak can be amelio-
rated bya covering ileostomyor not is still under debate.317,318
There are some small comparative studies, but no definitive
answer. However, when performing a coloanal anastomosis
after rectal excision for cancer, it is now established that a
covering loop ileostomy reduces the risk of clinical leakage.
Nevertheless, in pouch surgery it is sometimes clear at the
time of surgery that themorbidity associatedwith a stomawill
not justify its use, such aswhen there is a thick abdominal wall
and a short small bowel mesentery, as long as there have been
no problems constructing the anastomosis.319–321
7.2.7. Number of procedures to maintain competencyECCO statement 7G
An institution performing pouch surgery should do
more than ten cases per year [EL 5 RG D]
ECCO statement 7J
There are not enough data to give a recommenda-
tion on surveillance of pouches with respect to
malignant changes. However, patients operatedWhen performing complex surgical procedures that also
demand sophisticated perioperative care, it has been shown
that institutions performing larger numbers of operations
have better outcomes than those who only operate on such
cases occasionally.322 There are no details pertaining to IPAA,
but it seems reasonable to assume that this holds for pouch
surgery and the figure of ten per year for the unit is arbitrary,
but considered reasonable by surgical members of ECCO.
7.2.8. Salvage surgery for pouchesECCO statement 7H
Salvage surgery for complications of IPAA should
only be done in special centres with adequately
skilled staff and a reasonable number of proce-
dures performed per annum [EL5, RG D]From the perspective of a lifetime, failure rates for IPAA
will probably be in the region of 15%. Failure implies that the
patient has an ileostomy for an indefinite period, with or
without pouch excision. Failures are usually due to septic
complications or persistent pouch dysfunction, but some-
times the reason is a missed diagnosis of Crohn's disease with
fistulation, or refractory pouchitis. Before deciding that a
pouch has failed, the option of salvage surgery either as a
corrective procedure or a complete “redo” has to be consid-
ered. Thepatientwill invariably havea viewon this and it should
onlybeundertakenbycolorectal surgeonswith special expertise
in this area. Reported series of pouch rescue surgery describe a
salvage rate above 50% and a still acceptable functional
outcome.323–327 If pouch surgery is sufficiently complex to
recommend a minimum case-load each year for a unit, it seems
appropriate that salvage surgerywhich is evenmore challenging
should only be performed in unitswith a substantial case volume
load and expertise, although it is impossible to quantify a
‘reasonable number’.
7.3. Follow-up
7.3.1. General pouch follow upGeneral follow-up of people with an IPAA is a matter of
debate. There are no data to suggest that lack of follow-up
incurs any risk for the patient, disregarding the debate on
the risk of cancer. A proportion of patients (perhaps 20–30%)
will develop pouchitis (Section 8.1), which may be recurrent
or persisting. These patients will need continuing specialist
care, because primary care physicians or generalists will not
have the expertise necessary for management. The stapled
IPAA where there is a varying length of mucosa below the
anastomosis (see statement 7C, above), poses an additional
problem compared to the hand-sewn IPAA, since these
patients in principle have not had a curative procedure.
However the remaining mucosa represents a very minute
fraction compared to the original colon, which does not
represent a risk or clinical problem for most patients.316
7.3.2. Pouch surveillanceon for cancer or dysplasia should be followed long
term [EL5, RG D]The risk of malignant changes arising from the pouch
mucosa as a result of colonic metaplasia in the pouch has
generated much debate. Fewer than 30 pouch cancers have
been reported (2007), almost all in patients operated with
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primary surgery. Many of the cancers originate from
anorectal mucosal remnant, which is the basis of the
recommendation for mucosectomy (statement 7E,
above).314,315 The frequency of small bowel cancers in the
background population is very low and the risk of developing
a pouch cancer de novo is likely to be as uncommon, but
remains undefined.328
7.4. Fertility and delivery in patients with a
restorative proctocolectomy
7.4.1. Impact of pelvic surgery on fecundityECCO statement 7 M
No defined age limit for performing an IPAA can be
recommended [EL 5, RG D]
ECCO statement 7N
The continent ileostomy is still a viable option
that can be used when there is no possibility of
performing an ileal pouch anal anastomosis, or
when the IPAA fails for other reasons than
pouchitis, or when the patient specifically re-
ECCO statement 7K
In a fertile female patient the option of an ileorectal
anastomosis should always be considered, becauseIt has been convincingly demonstrated in three cohort
studies that female fecundity or fertility is reduced after
IPAA.329–332 The reason for this is most probably adhesions
affecting the fallopian tubes.333 The magnitude of this
problem is under debate, with one study showing N70%
reduction and the others demonstrating around 30% reduced
fecundity. There is however good evidence from a study on
patients with familial adenomatous polyposis, comparing
women with an ileo-rectal anastomosis (IRA) with those with
an IPAA, showing that there is no reduction in fecundity
associated with an IRA.334,335 This appears to be because an
IRA does not induce pelvic fibrosis to nearly the same extent
as an IPAA. This has lead to a modification in practice at some
centres, offering fertile female patients an IRA, provided the
rectum is not grossly inflamed, with a view to later pouch
surgery when the family is complete. Not every woman is a
candidate for this approach. Symptoms are less when there
has been a colectomy, since the inflamed colon has been
removed, but the rectum can be expected to remain in-
flamed. The persisting risk of rectal malignancy is discussed
in Section 7.5.3. On the other hand, IRA does not disturb
sphincter function, unlike IPAA, does not impair fecundity
and can be discussed as a temporising option.
7.4.2. Mode of delivery for patients with restorative
proctocolectomy
fecundity is at risk after IPAA [EL3b, RG B]ECCO statement 7L
With regard to bowel function a caesarean route of
delivery in a female with an IPAA is recommended
[EL 5, RG D]
quests this solution [EL 4, RG C]Vaginal delivery has a 0.5–3.5% risk of inflicting serious
maternal sphincter tears.336,337 The risk is highest at the
first delivery. On the other hand, multiple deliveries have
been shown to prolong pudendal nerve terminal motor
latency.338,339 People with an IPAA have a very limited
margin for maintaining faecal continence compared to thegeneral population. This is because many factors con-
sidered important for normal continence, such as solid
stools, rectal sensation, recto-anal nervous interplay
through a recto-anal inhibitory reflex, are absent in
people with an IPAA. Consequently they rely heavily on
their sphincter for maintaining continence. Principally on
these grounds many surgeons recommend that their
patient have a caesarian section rather than a vaginal
delivery. Nevertheless, in a cohort where caesarian
section was recommended only for obstetric reasons,
this group experienced very little or no difference in early
postoperative continence and bowel function.340 Although
it suggests that vaginal delivery is safe in selected cases,
it remains contrary to two other papers that support the
recommendation for caesarian delivery both in Europe and
the US.341,342
7.5. Surgical choices in addition to restorative
proctocolectomy
7.5.1. AgeFaecal continence in both men and women deteriorates
with increasing age. Females that have given birth carry a
higher risk of poor continence, probably because sub-clinical
injuries add to age-related changes in nerve function,
collagen elasticity and muscle strength. Consequently it is
reasonable to consider whether an upper age limit for IPAA
should apply. It has however been demonstrated that IPAA
will function reasonably well in people 70 years of age and
older in carefully selected cases.343–345
7.5.2. Continent ileostomyThe continent ileostomy (‘Kock pouch’) was the fore-
runner to the IPAA. It is a complex procedure with a high
potential for complications affecting the valve mechanism
that provides continence. However, with a functioning
continent ileostomy patients report excellent quality of life
with a next-to-normal body image.346–348 Furthermore a
failed pelvic pouch can still be converted to a continent
ileostomy, providing an alternative in those patients that
absolutely cannot accept a conventional stoma.325,349 A
major problem is that this operation is still performed at only
a few centres in Europe.
51ECCO Consensus on UC: Current management7.5.3. Ileorectal anastomosisECCO statement 7O
An ileorectal anastomosis should be considered only
in special cases (such as for reasons of fertility) [EL4,
RG C] ECCO statement 7R
Laparoscopic restorative proctocolectomy with an
IPAA is a feasible operation; it gives shorter scars
but there is no evidence for additional benefit to
the patient [EL 2a, RG B]An ileorectal anastomosis is historically burdened. It is not
only non-curative, but also leaves patients with the likelihood
of persistent symptoms from refractory rectal inflammation
and a risk of later cancer. Even so, recent series show a better
than expected durability, with half of the patients still living
with an IRA after 10 years.350,351 Its role in the management of
women facing surgery before they have completed their family
is discussed above (Section 7.4.1). It can be assumed that the
cancer risk with medical therapy and surveillance is at least
less than in those who have not had surgery.
7.5.4. Cancer surveillance of the rectal remnant after
colectomyECCO statement 7P
For patients who have a colectomy and ileostomy,
surveillance of the retained rectum is appropriate,
although it can be left in situ if the patient so
wishes [EL5, RG D]
ECCO statement 7S
In indeterminate colitis or colonic IBD yet-to-be
classified, an IPAA can be offered with the
information that there is an increased risk of
complications and pouch failure [EL4, RG C]The literature gives no direct guidance in this matter.
Some patients that come to colectomy with an ileostomy as a
first operation get accustomed to livingwith a stoma and have
very fewproblems from their retained rectum. If a patient has
no wish for further surgery, the question arises whether there
is any reason for rectal excision. The balance is between the
risk of a cancer in the disconnected bowel and the incon-
venience and risks of a proctectomy. Taking out the rectum is
amajor operation with a considerable surgical morbidity with
wound healing problems and risk of sexual dysfunction both in
women and men.352,353 Options of proctectomy or surveil-
lance of the retained rectal remnant should be discussed with
the patient.
7.5.5. Pouch excision after pouch failureECCO statement 7Q
In a patient where the pouch has failed and there is
no hope of re-establishing the anal route of defeca-
tion, there are not enough data to make any
recommendationonwhether or not thepouch should
be removed [EL5, RG D]
ECCO statement 7T
Prednisolone 20 mg daily or equivalent for more
for more than six weeks is a risk factor for surgical
complications [EL3b, RG C]. Therefore, corticos-
teroids should be weaned if possibleThe dilemma is similar in the patient with a failed,
disconnected pelvic pouch. Some of these patients do not
have any further pouch-related problems. There is as yet no
evidence that the risk of malignant change is increased in the
disconnected pouch. The morbidity of pouch excision is
probably no less than for proctectomy.324 For individuals whohave had severe septic complications, it is reasonable to
assume that the risk of pelvic nerve injury is increased.
7.5.6. Laparoscopic pouch surgeryMinimally invasive surgery is gradually being incorporated
into colorectal practice and is a feasible alternative for many
patients, provided that surgeons are adequately trained in
this technique. No randomised studies have yet shown any
major differences from open surgery.354,355
7.5.7. Pouch surgery for indeterminate colitis, or IBD yet-
to-be classifiedAbout 10% of patients with colitis will not have a definitive
diagnosis that discriminates between Crohn's and ulcerative
colitis. Terminology is discussed in Section 5. There are reports
of less favourable outcomes when performing pouch surgery for
patients with indeterminate colitis, although others find no
significant differences.356,357 Inmost series that report outcome
after pouch surgery, those with a secondary diagnosis of Crohn's
disease are burdened with very high complication and failure
rates. Although one group has reported outcomes equivalent to
those with UC for patients with a pre-operative Crohn's
diagnosis, none had pre-operative small bowel or perianal
disease.358 Pouch surgery for patients with a definitive diagnosis
of Crohn's disease cannot be recommended. For those inwhom it
is considered an option, very careful discussion with the patient
about increased risks of sepsis and pouch failure is appropriate.
7.6. Surgery and medication
7.6.1. Perioperative prednisoloneUncontrolled or retrospective series indicate that patients
takingN20mgprednisolone forN6weeks havean increased risk
of surgical complications.359,360 The rate of steroid reduction
after colectomy for acute severe colitis depends on the dose
52 S.P.L. Travis et al.and duration of steroids prior to surgery. Any recommendations
of the rate are arbitrary, but the aim is to avoid acute steroid
withdrawal (‘Addisonian’) crisis, characterised by hypoten-
sion, hyponatraemia and hypoglycaemia in its most severe
form. Milder symptoms may be disguised as a ‘slower than
normal’ recovery from surgery. There is little science to steroid
withdrawal. As a general guide, if patients have been on
corticosteroids for b1 month, steroids can usually be stopped
abruptly after surgery without ill effect. For those on steroids
for 1–3months, a reduction from20mg/dayafter colectomy of
5 mg/day each week is generally appropriate. For patients on
steroids for 3–6 months, a reduction of 2.5 mg/d each week is
probablymore appropriate, while for the occasional patient on
steroids for longer than 6 months, then a dose reduction of
1 mg/week (or even more slowly) is advisable.
7.6.2. Perioperative azathioprineECCO statement 7U
Pre-operative azathioprine does not increase the risk
of postoperative complications [EL3b, RG C]. Co-
lectomy for ulcerative colitis immediately following
or in the medium term after the use of ciclosporin
appears to have no higher rate of postoperative
complications [EL2b, RG D], while there are no
sufficient data yet available for infliximabAzathioprine does not appear to increase the risk of
surgical complications although debate continues.360–363
7.6.3. Perioperative anti-TNF therapy
TNFα is a key player in the immune response. Inhibition of
TNF by infliximab (IFX) or other agents could potentially lead
to serious post-operative complications. There is particular
concern that emergency colectomy within a few weeks of
infliximab may be associated with more septic complica-
tions. Even if IFX does not increase the risk of sepsis, it is still
likely that should a septic complication occur, then it will be
more severe in the presence of circulating anti-TNF antibody.
Whilst it is generally accepted that elective surgery for
Crohn's disease in the presence of IFX is not associated
with higher rates of sepsis,83,364 the same may not apply to
emergency colectomy for acute severe colitis (Section
5.2.5). In a Scottish survey 13/39 patients came to colectomy
after IFX treatment for acute severe colitis. One patient who
initially responded to infliximab died of septic shock from
bronchopneumonia 3 weeks after treatment, and another
had severe post-operative sepsis resistant to anti-bacterial
therapy and only responding to intensive antifungal treat-
ment.82 There has also been a worrying report of 20 patients
receiving ciclosporin (for a mean 3.8 months, range 0.5–
12.2) before IFX, or IFX (mean 2 infusions, range 1–3) before
ciclosporin for severe steroid-refractory colitis.365 One pa-
tient died from E. coli septicaemia, another became
jaundiced and another developed herpetic oesophagitis.
Such therapy in combination in an endeavour to avoid
colectomy carries high risks and cannot be recommended.
Similar concerns have been raised from the Mayo clinic
relating to IPAA after IFX.366 Between 2002 and 2005, 47
patients received IFX before IPAA, and 254 patients receivednone. IFX patients were younger than non-IFX patients (mean
age 28.1 to 39.3 years, pb0.001), probably reflecting
concern that all medical options were explored before sur-
gery. Overall surgical morbidity was similar (61.7% and
48.8%, IFX and non-IFX respectively, p=0.10), with no
mortality. Anastomotic leaks (p=0.02), pouch-specific
(p=0.01) and infectious (pb0.01) complications were more
common in IFX patients. Multivariate analysis revealed IFX as
the only factor independently associated with infectious
complications (OR 3.5; 95%CI 1.6–7.5). When age, corticos-
teroid dose, azathioprine, and severity of colitis were
factored into the analysis, IFX remained significantly as-
sociated with infectious complications (OR 2.7; 95% CI, 1.1–
6.7). This illustrates the need for caution when using IFX in
the perioperative period of severe colitis.
7.7. Colectomy in practice
The rate of colectomy varies according to the patient
cohort, duration of follow up and geographical location.
Studies published in the early 1990 s reported an overall
colectomy rates of 23%, 28% and 34% after 10 years of follow
up, with rates as high as 35% at 5 years and 42% and 54% at
10 years for extensive colitis.367–369 It is unclear whether
the overall rate is changing, even in areas with excellent
population-based data such as Copenhagen, where there
has traditionally been a high rate of colectomy. When
patients diagnosed with UC in Copenhagen during 2003–
2005 were followed prospectively only 6% of patients
underwent surgery during the year of diagnosis, signifi-
cantly less than earlier reported.370 This might reflect an
increasing prevalence of proctitis and milder initial course
diagnosed in the 1990s, but when 3 consecutive population-
based IBD cohorts from Copenhagen (1962–2005), were
assessed the cumulative surgery rate in 1575 patients with
ulcerative colitis did not decrease significantly.195 Never-
theless, in a 781 patient European inception cohort (1991-
93) from 7 countries, the overall 10 year cumulative risk of
colectomy was only 8.7%.371 Colectomy rates for extensive
colitis at diagnosis in Denmark, Norway and the Netherlands
were 22.1% compared to 8.5% for Greece, Italy, Spain and
Israel. The extent of disease did not differ between
northern and southern centres, but the prevalence of
proctitis or distal colitis was remarkably high (75%, or
557/745 patients). This is as likely to explain the low overall
colectomy rate as are cultural differences or acceptance of
symptoms between countries. The 10 year colectomy rate
was 2% for proctitis/distal disease, 18% for extensive
disease at diagnosis, and 39% for the 11% (62/557) patients
with proctitis progressing to extensive colitis during follow
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